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After decades of methodologic developments and groundbreak-
ing applications in basic and clinical neuroscience, in vivo mag-
netic resonance spectroscopy (MRS) has become a mature
technique for metabolic studies of the central nervous system. In
particular, localized proton MRS significantly adds to the increas-
ingly important role of magnetic resonance imaging (MRI) in trans-
lational medicine. Complementing advances in fluorescence
microscopy at the lower spatial scale, noninvasive MRI and MRS
are indispensable tools that offer unique links between molecular
neurobiology and clinical research.
This work reviews proton MRS studies of mammalian brain and
ignores sparse applications to other vertebrates and insects. It fo-
cuses on mice [1–30], rats [31–101], and nonhuman primates
[102–130] with a complementary section on gerbils [131], squir-
rels [132], cats [133–140], dogs [141–146], sheep [147,148], and
swine [149,150]. Moreover, this contribution entirely features
in vivo MRS studies and leaves out investigations of organs
in situ, excised tissues, brain slices, or cell cultures.
The main purpose is to illustrate the potential of cerebral MRS
in preclinical research. Rather than providing a comprehensive sur-
vey, emphasis will be placed on animal models of human brain dis-
orders that rely on rodents and nonhuman primates. This selection
is motivated by the fundamental advances in mouse neurogenetics
and the close homology of monkeys with humans. As far as techni-
cal considerations are concerned, most current MRS studies
achieve spatial localization with the use of a point-resolved spec-
troscopy (PRESS) [151–153] or stimulated echo acquisition mode
(STEAM) [154,155] sequence. Early studies without spatial locali-
zation are only included if of historic interest. Moreover, MRS re-
ports that failed to present a single spectrum are usually
discarded because such publications do not allow for a proper
judgement of the scientific quality and significance of the MRS
findings.
In humans, proton MRS studies of the central nervous system
have repeatedly been reviewed, for example see [156–163]. On
the other hand, reviews of animal studies have mainly addressed
specific aspects of technical feasibility [164–168] or the occurrence
of metabolic alterations in selected disease conditions [169–180].
In contrast, this review first discusses the basic requirements fora successful MRS study of animal brain and then focuses on the
most common models of human brain disorders.
2. Localized proton MRS of animal brain in vivo
2.1. Animals and anesthesia
The choice of a species for answering a particular biological or
medical question with the use of an animal experiment is a com-
plex decision taking into account animal welfare, practicality,
and scientific rationale. Apart from ensuring the best scientific
suitability, experimental considerations have to include availabil-
ity, cost, animal husbandry, and possible transportation. Because
models of human brain disorders are often not restricted to a spe-
cific species, the majority of localized proton MRS studies have
hitherto been performed in rats. These studies are less expensive
than those of nonhuman primates, and rats offer a larger brain than
mice. In fact, in comparison to mice, rat studies often achieve a
higher signal-to-noise ratio (SNR) and offer more robust and better
controllable physiological conditions under anesthesia. However,
due to the rapid development of mouse neurogenetics, mouse
models are becoming increasingly important for investigations of
the genetic control of cellular metabolism and physiological pro-
cesses as well as related disturbances.
Complementary, nonhuman primates are the only species that
offer a close similarity to humans in terms of anatomical, physio-
logical, immunological, and functional properties of the central
nervous system. Although monkey models are likely to remain lim-
ited in number and expected to preferentially address novel ther-
apeutic trials previously developed in rodents, they will be
required for specific neurological disorders (e.g., multiple sclerosis)
and psychiatric syndromes (e.g., stress and depression).
An obvious difference between human and animal MRI and
MRS studies is the need for anesthesia in the animal studies in or-
der to minimize stressful effects and to avoid undesired artifacts
due to movements. Protocols for anesthesia vary for different spe-
cies and sometimes also for different sites. They may also depend
on the initial access to the awake animal, the total examination
time, and the actual scientific question. If the animal is required
for subsequent histology and does not need to recover from anes-
thesia, invasive approaches such as tracheotomy might be appro-
T. Michaelis et al. / Progress in Nuclear Magnetic Resonance Spectroscopy 55 (2009) 1–34 3priate. However, because of the growing demand for follow-up
MRS measurements, alternative techniques are intravenous injec-
tions, spontaneous breathing of an anesthetic gas via a mask, or
endotracheal intubation with artificial ventilation which is the
standard procedure in this laboratory. Once established the latter
strategy outperforms other methods with respect to animal safety
and recovery rate, the ability to perform adjustments during the
experiment, and the realization of measuring times of up to several
hours. Although experimentally demanding, intubation has turned
out to be extremely valuable for investigations of young and aged
animals, severely affected animals, and rare mutants with an often
unknown pathophysiological background.
After initiation of anesthesia animals are commonly placed in
a prone or supine position on a commercially available or cus-
tom-built bed (animal slider). In many cases a stereotaxic device
is used to immobilize the head. Noninvasive monitoring of basic
life functions such as breathing amplitude and frequency, blood
oxygenation level, and rectal temperature are usually sufficientFig. 1. Experimental setup for localized proton MRS of mouse brain in vivo at 9.4 T. W
shown), signal reception employs an actively decoupled quadrature surface coil position
the mouse warm, a home-made stereotaxic palate holder with an adjustable nose cone,
thermometer. Courtesy of Dr. Roland Tammer (rtammer@gwdg.de).to control anesthesia and ensure adequate survival rates. Other
features involving permanent catheters or electrodes for electro-
physiological recordings may be necessary for special
applications.
2.2. Experimental setup
The majority of animal MRS studies employ a surface coil for
signal reception either in transmit/receive mode or in combination
with a homogeneous radiofrequency (RF) excitation coil. Although
this choice is generally motivated by clear SNR advantages for vol-
umes-of-interest (VOI) close to the surface coil, it may also suffer
from a fading signal for VOIs at increasing distance from the coil.
The coils must be perpendicular to the static magnetic field and
geometrically and/or actively decoupled. Best results in terms of
SNR are obtained by placing the head of the animal (partly) within
a single-looped circular or elliptic surface coil. When actively
decoupled, slightly bent coils may be adapted to the shape of thehile signal excitation is accomplished with the use of a homogeneous RF coil (not
ed on top of the mouse head. The animal holder and bed comprise a means to keep
a connection to a respirator for artificial ventilation, a pressure sensor, and a rectal
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Fig. 2. Localized proton MRS (STEAM) of metabolite solutions at a low field
strength (2.35 T, TR/TE = 10,000/10 ms) and a high field strength (9.4 T, TR/
TE = 15,000/10 ms). (Top) 1:1 mixture of myo-inositol (Ins) and creatine (Cr) and
(bottom) 2:2:1 mixture of N-acetylaspartate (NAA), glutamate (Glu), and
glutamine (Gln). While Ins is easily detectable at low fields due to its apparent
singlet resonance, a much better separation of Glu and Gln is achieved at high
fields.
4 T. Michaelis et al. / Progress in Nuclear Magnetic Resonance Spectroscopy 55 (2009) 1–34head. Fig. 1 illustrates the setup used in this laboratory for MRS of
mouse brain at 9.4 T. Further advantages in SNR emerge from the
use of phased array coils, which are now commercially available
for most field strengths/frequencies used for animal research.
Animal MRI systems feature higher magnetic field strengths,
smaller bore sizes, and stronger gradient systems than most hu-
man MRI systems. The relative merits of high versus low magnetic
fields are still a matter of debate, even for localized proton MRS
in vivo [181–185]. Fig. 2 demonstrates complementary advantages
of a low and high magnetic field strength for the resolution of indi-
vidual (spin-coupled) metabolite resonances. At 2.35 T, proton
spectra of a mixture of myo-inositol (Ins) and creatine (Cr) have a
superior peak intensity ratio due to the apparent singlet resonance
of Ins which translates into a better relative detectability at low
magnetic fields. Conversely, proton spectra of a mixture of N-acet-
ylaspartate (NAA), glutamate (Glu), and glutamine (Gln) demon-
strate that the improved separation of the Glu (2.35 ppm) and
Gln multiplets (2.45 ppm) at 9.4 T leads to a better detectability
at high magnetic fields. In order to fully exploit the advantage of
a larger chemical shift dispersion, it is recommended to use ad-
vanced shimming techniques such as FASTMAP [186] in conjunc-
tion with sufficiently strong shim currents.
In general, high magnetic field strengths offer a gain in SNR that
maybebest realizedwith theuseofshortechotimeMRSacquisitions.
This advantage allows for the investigation of small VOIs that are re-
quired for cerebral subregions such as the mouse hippocampus. On
theotherhand,protonMRSof largeranimalsmaysuccessfullybeper-
formed at lower fields as demonstrated for nonhuman primates
which have mainly been studied in clinical systems at 1.5 T [106–
108,110–115,117–119,123–125,127,128] and 3.0 T [116,129].
2.3. Localization
The first in vivo MRS studies of animal brain were carried out
without spatial localization and therefore suffered from a variety
of systematic problems. Typically, surface coils were either placed
directly on the brain or skull or even chronically implanted, for
example see studies of mice [187–190], rats [191–195], gerbils
[196–199], guinea pig [200], rabbits [201–206], cats [207–209],
dogs [210–215], sheep [216,217], and swine [218–220]. Because
the sensitivity profile of the surface coil alone is not sufficient to
properly focus on a particular VOI and to exclude signal contami-
nation from surrounding tissue, such studies remained a historic
episode that ended with the advent of single-voxel localized MRS
[151–155] and chemical shift imaging [221–223] also termed mag-
netic resonance spectroscopic imaging (MRSI). In either case, the
actual localization of a VOI or reduced field-of-view for spectro-
scopic imaging is commonly accomplished with the use of a PRESS
or STEAM sequence as schematically indicated in Fig. 3. For proton
MRS, these sequences are preceded by a water suppression module
such as the generic CHESS method [224], that is a water-selective
RF excitation pulse followed by a spoiler gradient. Relative advan-
tages and drawbacks of MRS versus MRSI and PRESS versus STEAM
have been discussed elsewhere [225–229]. Because all techniques
may perform high-quality proton MRS in vivo when properly used,
other non-technical issues such as the quantification of metabolite
concentrations (rather than the observation of resonance intensity
ratios) are more important in view of the achievable neurochemi-
cal insight or long-term medical impact.
In general, the aforementioned techniques ensure adequate
spatial resolution for studies of regional brain metabolism in anes-
thetized animals. With regard to field strength, investigations of
mice have been remarkably improved by high magnetic fields.
For a reasonable SNR and measuring times of 15 min, the mini-
mum VOI for high-field proton MRS is on the order of

















Fig. 3. Generic localization sequences for in vivo proton MRS using spin echoes (PRESS) or stimulated echoes (STEAM).
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250 100 500 lm3 which further attenuates the SNR by a factor
of 80 and therefore causes unrealistic measuring times. It is impos-
sible that higher magnetic fields are able to solve this limitation,
because current magnets are already close to the technical limit
of about 20 T. Moreover, field-dependent increases in T1 and de-
creases in T2 relaxation times partly counterbalance the enhanced
spin polarization and compromise the achievable gain in SNR per
unit time.
2.4. Metabolites
A large number of cerebral metabolites has been identified in
localized proton MR spectra of animal brain in vivo [230–237]. Un-
der normal physiological conditions the frequency range between
1 and 4 ppm comprises resonances of lactate (Lac), alanine (Ala),
acetate, NAA, N-acetylaspartylglutamate (NAAG), c-aminobutyric
acid (GABA), Glu, Gln, aspartate (Asp), Cr, phosphocreatine (PCr),
choline-containing compounds (Cho), taurine (Tau), glucose
(Glc), Ins, scyllo-inositol, glycine, glutathione, phosphoethanol-
amine, vitamin C, and threonine as well as of macromolecules
(MM) and (un)-saturated lipids. Under pathological conditions
or after drug administration additional metabolites may become
detectable including ethanol, methanol, glycerol, acetone, pro-
pan-1,2-dyol, guanidinoacetate, pyruvate, and succinate (Suc).
The list of detectable metabolites also includes compounds with
resonances in the aromatic part of the proton MR spectrum, that
is beyond 5 ppm.
Often NAA and NAAG (tNAA), Cr and PCr (tCr), and Cho are con-
sidered as ‘‘major” metabolites. This is mainly due to their rela-
tively high concentrations and the singlet nature of their methyl
resonances. Together these features lead to a certain ease of detec-tion even at long echo times and/or low SNR. Similar arguments
apply to the doublet resonance signal from Lac when its concentra-
tion increases above normal physiological levels. Short echo times
facilitate the direct observation of additional resonances from Ins,
Glu, and Gln, and in some cases also of Glc (e.g., at low fields in ro-
dents and monkey brain) and Tau (e.g., at high fields in mouse
brain).
Most of these metabolites are involved in important physiolog-
ical processes and often represent a specific cell type. Thus, dis-
ease-related alterations of respective metabolite levels may
reflect both changes in intracellular metabolism and tissue compo-
sition. For example, the metabolite pattern may be characteristic
for the cerebral energy status, the glial cell population, or the neu-
roaxonal integrity and function. Briefly, NAA has been demon-
strated to be predominantly localized within neurons [238–243]
and is commonly considered as a marker for vital neuroaxonal tis-
sue. The energy metabolites Cr and PCr are linked to oxidative
phosphorylation and mitochondrial function and are constituents
of both neuronal and glial cells [240]. A pathological loss of neu-
rons as suggested by reduced NAA therefore causes a similar
reduction of tCr unless compensated for by increased glial cell den-
sity (e.g., due to reactive astrogliosis). Elevated concentrations of
Lac indicate enhanced nonoxidative glucose consumption, not only
in brain cells but also due to the anaerobic metabolism of infiltrat-
ing macrophages (e.g., during neurodegeneration). The Cho reso-
nance comprises phosphocholine as a precursor for membrane
synthesis as well as glycerophosphocholine as the corresponding
membrane degradation product. Accordingly, elevated Cho con-
centrations may either arise from enhanced membrane turnover
(e.g., during development or in brain tumors) or from accumula-
tion of myelin breakdown products (e.g., during active demyelina-
tion). A diminished Cho level has been described in Pelizaeus–
ig. 4. Feasibility of localized proton MRS of mouse brain in vivo (4.7 T, PRESS, TR/
E = 2500/20 ms, 2 2 2 mm3, 128 accumulations). This early application corre-
onds to the normal and ischemic hemisphere of a C57BL/6J mouse 3.5 h after
cclusion of the middle cerebral artery. The accumulation of Lac is accompanied by
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arises from free myo-inositol, which is the most important non-
nitrogenous organic osmolyte in the brain with very high concen-
trations in astrocytes [239]. Thus, elevated Ins concentrations are
most often interpreted as increased cellular density of astrocytes
(e.g., due to astrocytosis or in glial tumors).
In view of their manifold roles it is not surprising that even the
limited set of MRS-detectable metabolites allows for a biochemi-
cally relevant and medically important characterization of brain
tissue under physiological and pathological conditions. This has
been discussed in detail for both humans [156–163] and animals
[164–180]. Here, a closer insight into possible metabolic pathways
will be confined to the disease models presented in subsequent
sections.
2.5. Quantification
In order to facilitate a sound interpretation of MRS findings, it is
preferable to translate the observation of a spectroscopic alteration
into a biochemical quantity such as a metabolite concentration.
Thus, a first desirable step is the minimization of T1 and T2 effects
during data acquisition. Similar to relaxation effects in MRI that
give rise to pathological contrast, also metabolite relaxation times
are usually altered in a disease condition. To avoid time-consuming
measurements of the actual relaxation times for corrections of T1-
and T2-weighted spectra, it is therefore advisable to choose suit-
able acquisition parameters such as long repetition times
(TRP 5  T1) and short echo times (TE T2). Because long TR val-
ues result in excessive measuring times for MRSI, this strategy is
only applicable to single-voxel MRS. Spatial mapping of metabolite
distributions by MRSI and quantitative evaluations of metabolite
concentrations by single-voxel MRS are therefore complementary
strategies for investigating brain metabolites.
A second step during data analysis is to avoid the use of relative
peak heights or intensities (areas) of individual resonances.
Although in some cases the use of metabolite ratios (e.g., relative
to tCr) might be sufficient to qualitatively identify a neurochemical
disturbance, many pathologies involve alterations in cellular den-
sity and therefore affect the tCr level as well. Ratios therefore bear
the risk of missing simultaneous concentration changes.
A third important step toward metabolite quantification is an
attempt to obtain absolute concentrations with the use of an inter-
nal (e.g., brain tissue water) or external reference. In humans, sev-
eral approaches have been developed to quantify cerebral
metabolite concentrations for homogeneous RF coils [245–250].
With appropriate adjustments these methods may also be adapted
to surface coils [62] or even phased array coils [251]. Finally, spec-
tral evaluations should be performed in an objective manner, that
is fully automatic and without user interference. Available soft-
ware packages such as LCModel [252,253] supply estimated
metabolite concentrations as well as measures of reliability (e.g.,
Cramer–Rao lower bounds). Some general conditions for MRS
quantitation have recently been reviewed for human studies [254].
2.6. Summary
State-of-the-art localized proton MRS of animal brain in vivo re-
quires the consideration of a number of technical components: (i)
the design of an appropriate experimental setup; (ii) the optimiza-
tion of a short echo time MRS or MRSI localization technique based
on PRESS or STEAM; (iii) a calibration method for quantification of
metabolite concentrations; (iv) an objective and reliable spectral
evaluation method. In addition, a sound interpretation of MRS find-
ings strongly depends on a profound understanding of the physio-
logical functions of MRS-detectable metabolites.3. Mouse models
The first proton MRS studies of mouse brain in vivo were per-
formed without spatial localization by placing a surface coil on
the skull or even directly onto the exposed brain [187–190]. De-
spite residual contributions from superficial skin, muscle, and fat,
this simple approach allowed for investigations of the mouse brain
metabolism that paved the way to fully localized acquisition tech-
niques and the analysis of more sophisticated (genetic) mouse
models. In fact, the very first study in 1986 already dealt with an
inborn error of metabolism by comparing the normal cerebral
metabolite profile with that of mutant histidinaemic mice [187].
Further examples refer to a mouse model of scrapie [188], a trans-
genic mouse overexpressing the human ornithine decarboxylase
gene [189], and a mouse model of Duchenne muscular dystrophy
[190]. Although these studies demonstrated the unique potential
of proton MRS in vivo, the need for technical improvements in
small animal MRS as well as the only more recent availability of
genetically modified animals hampered the development of mouse
brain MRS for about a decade. Fig. 4 shows the results of a feasibil-
ity study from 1998 which for the first time offered fully localized
proton MRS of the normal and ischemic mouse brain [1].
3.1. Normal physiology
Localized proton MR spectra of normal mouse brain are de-
picted in Fig. 5 for two different field strengths. The list of readily
accessible metabolites includes tNAA, tCr, Cho, Ins, Glc, Tau, and
Glu. While low fields (here 2.35 T) facilitate the detection of Ins
and Glc because their strongly spin-coupled multiplets merge into
apparent singlet resonances, the identification of Tau and Glu (sep-
arated from Gln) is more easily achieved at high fields (here 9.4 T)
yielding improved spectral resolution due to the enhanced chemi-
cal shift dispersion. On the other hand, the increasing linewidths at
higher fields are generally larger than most coupling constants and,
for example, preclude the resolution of the weakly coupled doublet
resonances obtained for Lac (7 Hz, centered at 1.33 ppm) and Ala
(7 Hz, centered at 1.48 ppm) which is easily achieved at lower
fields. Accordingly, the neurochemically important determination




decreases of NAA, tCr, and Cho (arrows). Adapted from Ref. [1] with permission.
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Fig. 5. Localized proton MRS of mouse brain in vivo (NMRI) at different field
strengths. In comparison to low field acquisitions (2.35 T, STEAM, TR/TE = 6000/
20 ms, 4:0 3:0 4:0 mm3, 512 accumulations) the use of a high field (9.4 T,
STEAM, TR/TE = 6000/10 ms) allows for either a much lower number of accumu-
lations (32 accumulations) or a much smaller volume (2:0 1:2 2:2 mm3
covering the hippocampus) at still reduced measuring time (128 accumulations).
Metabolite resonances refer to tNAA, Glu, tCr, Cho, Ins, Tau, Glc, and MM.
Table 1
Proton MRS linewidths of mouse brain in vivo for different magnetic field strengths
(in T) and volumes-of-interest (VOI).
Field/T VOI/mm3 Linewidth/Hz Reference
2.35 4:0 3:0 4:0 7–9 [8]
4.7 3:4 1:7 1:7 18 [17]
4.7 6:0 3:5 3:0 11 [2]
7.0 2:0 2:0 2:2 13–17 [29]
9.4 2:0 1:5 2:5 10–14 [12,28]
9.4 1:5 1:5 1:5 12–20 [21]
9.4 2:5 2:5 2:5 20 [18]
ig. 6. Mouse brain in vivo (C57BL/6-SJL) during maturation. Localized proton MRS
.4 T, PRESS, TR/TE = 2000/130 ms, 2 2 2 mm3, 512 accumulations) of the
alamus as a function of postnatal age (days 5–21) reveals spectral alterations such
s an increase of NAA and decrease of Tau. Adapted from Ref. [21] with permission.
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ids and/or macromolecules. Table 1 summarizes the linewidths of
water proton resonances that have been reported for mouse brain
in vivo in a number of experimental settings. The values range
from 7 Hz (2.35 T) to 20 Hz (9.4 T) depending on field strengthF
(9
th
aand size of theVOI. Further influences are due to regional differences
in selected brain areas and may also reflect the investigated mouse
strain. In general, the most important advantage of a high field is
theenhancedspinpolarizationwhichmaybe translated intoabetter
SNR. This gain provides access to adequately small VOIs that allow
for a meaningful metabolic assessment of mouse brain structures
such as the hippocampal formation (compare Fig. 5).
Proton MRS has been used to monitor metabolic alterations
during brain maturation in the mouse thalamus, olfactory bulb,
and cerebellum [21]. Fig. 6 shows serial proton MR spectra from
the thalamus for postnatal days 5–21 that reveal increased NAA
and Glx signals as well as decreased Cho and Tau resonances as a
function of age. After correcting for significantly increased T2 relax-
ation times, the alterations may be assumed to reflect true changes
in metabolite concentration. In fact, similar changes of NAA, Cho,
Tau, and Glx concentrations during brain maturation were found
in rats and humans. Between 4 and 24 months of age the NAA/
tCr ratio in mouse brain was reported to remain unchanged [17]
or to be slightly reduced [18]. In adult mice, regional concentration
differences of cerebral metabolites have been reported either in
terms of metabolite ratios to tCr as obtained by proton MRSI
[22,23] or, more directly, as absolute metabolite concentrations
by quantitative proton MRS [10,12,21]. Localized proton MR spec-
tra of the mouse cerebral cortex, hippocampus, striatum, and cer-
ebellum are compared in Fig. 7 [12]. Qualitatively, the respective
metabolite profiles exhibit a close similarity to those observed in
other mammals such as rats, monkeys, and humans.
It shouldbenoted that subtle thoughdistinctdifferencesexist be-
tween different mouse strains. Several authors compared metabo-
lite levels in NMRI, BALB/c, and C57BL/6 mice [8], CBA, CBA/BL6,
and C57BL/6 mice [12], and 129/SvJ, FVB/N, and C57BL/6 mice
[27]. The finding of differentmetabolic endophenotypes is of partic-
Fig. 7. Regional metabolite profiles of mouse brain in vivo (C57BL/6) as detected by localized proton MRS (9.4 T, STEAM, TR/TE = 5000/2 ms) of the cerebral cortex
(2:5 1:2 3:0 mm3, 320 accumulations), hippocampus (2:0 1:2 2:2 mm3, 320 accumulations), striatum (1:7 2:0 3:0 mm3, 160 accumulations), and cerebellum
(2:0 1:7 1:8 mm3, 320 accumulations). Adapted from Ref. [12] with permission.
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popular background strains for the genetic engineering of mouse
models. As an example, Fig. 8 compares in vivo and early postmor-
tem proton MR spectra of the brain of NMRI, BALB/c, and C57BL/6
mice [8]. While MRI volumetry of the C57BL/6 strain yielded the
largest ventricular spaces, proton MRS resulted in elevated concen-
trations of tNAA, tCr, Cho, Glc, and Lac relative to BALB/c mice and
elevated Glc relative to NMRI mice. Significant morphological and
metabolic heterogeneity was also reported for the 129/SvJ, FVB/N,
and C57BL/6mouse strains [27]. MRI volumetry not only confirmed
the enlarged ventricular volume of the C57BL/6 strain, but in addi-
tion revealed significant alterations in cerebellar and hippocampal
volume as well as differences in the thickness of the motor cortex.
As far as metabolite levels are concerned, only metabolite ratios to
tCr were reported, but the results are again in line with previous
observations [8] yielding the highest tCr level and lowest NAA/tCr
ratio in the C57BL/6 strain. In CBA, CBA/BL6, and C57BL/6 mice stri-
atal concentration differences for Lac, NAAG, Glu, Gln, Ins, and phos-
phoethanolamine were found to be small [12].
In summary, in vivo metabolite concentrations that have been
reported for mice as a function of age, brain region, and strain
are in good agreement with values determined by in vitro proton
NMR spectroscopy of brain tissue extracts [255–258] and qualita-
tively similar to the metabolite profiles of other mammal brains.
3.2. Cerebral ischemia
Cerebral ischemia refers to a condition where the brain or parts
of it do not receive sufficient blood flow (i.e., oxygen and glucose)to maintain normal physiological function. Decreased blood flow
may be caused by blockage or obstruction of the supplying arterial
vessels. If severe or prolonged, brain ischemia results in an acute
stroke leading to unconsciousness, tissue damage, or death.
In a C57BL/6 mouse model of focal cerebral ischemia, Fig. 4
demonstrates a pronounced increase of Lac in the affected brain
hemisphere and a distinct decrease of NAA 2 h after occlusion of
the middle cerebral artery. The lack of oxygen supply causes a fail-
ure of the energy metabolism which involves a switch from oxida-
tive phosphorylation to nonoxidative glucose consumption. This
latter process utilizes local glygocen stores and produces Lac. The
concomitant spectral reductions of Cho and tCr may be understood
as a dilution of all metabolites due to the developing vasogenic
edema which widens the extracellular space by influx of water
from the capillary bed [1]. These responses to ischemia are in line
with a quantitative study of global ischemia in C57BL/6 mice 1 h
after cardiac arrest as shown in Fig. 8. Noteworthy, apart from
the unavoidable changes in Glc and Lac concentrations, no signifi-
cant reductions of tNAA, tCr, and Cho are observed in BALB/c and
NMRI mice [8]. The results support the hypothesis that the en-
hanced vulnerability of C57BL/6 mice to cerebral ischemia is linked
to strain-dependent differences of the cerebral energy metabolism
and/or the formation of edema.
In view of the tremendous amount of work on cerebral ischemia
using rat models, new insights are required to justify the use of
respective mouse models. A novel line of research could possibly
arise from transgenic mice that are designed to model specific
pathophysiological processes and neurochemical alterations in re-
sponse to ischemia.
Chemical Shift / ppm ChemicalShift / ppm
Fig. 8. Cerebral ischemia in different mouse strains. Localized proton MRS (2.35 T, STEAM, TR/TE = 6000/20 ms, 4 3 4 mm3, 512 accumulations) of the brain in vivo and
1 h postmortem (same animal) for a (top) NMRI, (middle) BALB/c, and (bottom) C57BL/6 mouse. Apart from decreased Glc and increased Lac concentrations postmortem, the
specific vulnerability of the C57BL/6 strain to ischemia is demonstrated by severely reduced levels of tNAA, tCr, and Cho (arrows). Adapted from Ref. [8] with permission.
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In humans, proton MRS is widely used to elucidate brain lesions
in multiple sclerosis. The pathophysiology of multiple sclerosis is
characterized by inflammation, demyelination, and axonal dam-
age. Although the exact etiology is still unknown and subject of
ongoing research, a large variety of animal models ranging from
monkeys to mice have been developed that mimic the pathologic
conditions of multiple sclerosis. The most frequently used animal
model of multiple sclerosis is experimental allergic encephalomy-
elitis (EAE) which in rodents leads to inflammatory demyelination
mainly in the spinal cord. Because of a lack of EAE mouse models
with robust cerebral involvement, most in vivo studies address
morphological alterations using MRI rather than disturbances of
tissue metabolism or cellular composition using MRS. To partially
overcome this problem Theiler’s murine encephalitis virus infec-tion, an established model of demyelinating diseases, has been
investigated in C57BL/6J mice [259]. At 3–7 days after intracerebral
virus injection serial T1-weighted MRI and proton MRS (spectra not
shown) revealed periventricular and parahippocampal hypoin-
tense lesions with decreasing NAA/tCr and Cho/tCr ratios. Normal-
ization of the MRI hypointensities 45 days after injection was
accompanied by a normalization of the NAA/tCr and Cho/tCr ratios,
suggesting active regeneration.
In order to further advance our knowledge of the mechanisms
regulating disease progression and tissue repair in multiple sclero-
sis, more correlations of proton MRS in vivo and histopathologic
assessments are warranted. Pertinent studies may range from con-
ventional mouse models of reversible demyelination (e.g., after
feeding of the toxin cuprizone) to highly specific transgenic models
of selected pathophysiologic mechanisms that lead to demyelina-
tion and/or axonal damage.
ig. 9. Transgenic mouse model of Huntington’s disease. Localized proton MRS
.7 T, PRESS, TR/TE = 2000/136 ms, 6:0 3:5 3:0 mm3, 256 accumulations) of the
riatum of a N171-82Q mouse with 82 cytosine–adenosine–guanosine (CAG)
peats, a YAC72 mouse with 72 CAG repeats (low expression level), and a wild-
pe (WT) YAC mouse. The NAA/tCr ratio decreases with increasing length of CAG
peats. Adapted from Ref. [19] with permission.
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Parkinson’s disease is a chronic motor system disorder which
results from a progressive loss of dopamine-producing cells in
the substantia nigra. The reduced level or even lack of dopamine
leads to a generalized slowness of movements (bradykinesia),
muscular rigidity, and tremor which is most noticeable during rest.
Degeneration of nigrostriatal dopaminergic neurons as the
pathologic hallmark of Parkinson’s disease can be induced by 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication
[15,24]. Quantitative proton MRSI in MPTP-treated mice demon-
strated a significantly decreased NAA concentration on days 2
and 6 after MPTP injection in the substantia nigra pars compacta
and striatum, regions most affected in human disease. More inter-
estingly, MPTP-intoxicated mice that received immune cells
(recovered from copaxone-vaccinated animals) presented with
similar NAA levels as found in sham-treated animals, whereas
adoptive transfer of immune cells from ovalbumin-immunized
animals to MPTP-treated mice failed to prevent lower NAA levels
and to protect dopaminergic neurons and their projections [15].
Another proton MRS study reported increased striatal Lac/tCr
ratios as quickly as 2 h after MPTP injection which returned to ba-
sal levels 7 h after injection [24]. Pre-treatment with deprenyl, a
monoamine oxidase B inhibitor, or with GBR-12909, a dopamine
uptake inhibitor, almost completely attenuated both the increases
in striatal Lac/tCr ratios and the subsequent loss of dopaminergic
nerve terminals in MPTP-treated mice [24]. These results suggest
the potential of proton MRS to detect metabolic alterations in Par-
kinson’s disease and monitor disease progression and treatment.
3.5. Huntington’s disease
A relatively large number of proton MRS studies has been per-
formed in transgenic mouse models of Huntington’s disease. The
progressive neurodegenerative disorder is due to a genetic defect
of a lengthened cytosine–adenosine–guanosine (CAG) sequence,
which codes for an expanded polyglutamine tract in the huntingtin
protein. Several transgenicmousemodels have been developed that
differ in CAG repeat length. For example, N171-82Q mice with 82
CAG repeats exhibit a progressive neurological phenotype at about
3 months of age with a mean death shortly after [6,19]. Mice of the
R6/1 line with 111–121 CAG repeats show progressive symptoms
by 4–5 months of age and therefore serve as an adult-onset model
[3]. The more intensively studied R6/2 mice with 150 CAG repeats
developfirstbehavioral symptomsat about1–2monthsandare con-
sidered to model juvenile-onset Huntington’s disease [2,13,19,28].
In all studies, proton MRS is employed to assess the neurochemical
profile of the striatum during disease progression.
Longitudinal measurements of relative metabolite ratios in the
juvenile R6/2 mouse model revealed a pronounced nonlinear drop
of striatalNAA levels startingat about6weeksof age coincidentwith
the onset of symptoms. Histopathology after natural death demon-
strated that the in vivo NAA/tCr reduction did not reflect neuronal
death but neuronal dysfunction [2]. Decreased striatal NAA levels
were also found in other proton MRS studies, while Cho and/or tCr
levels were not altered in R6/1 mice [3] and elevated in R6/2 mice
[13,28]. As demonstrated in Fig. 9, the severity of the NAA reduction
strongly correlated with the CAG repeat length as well as with the
levels of gene expression and protein context [19].
Behavioral testing and proton MRS have been used to assess
therapeutic effects of various drugs in transgenic mouse models
of Huntington’s disease. Thus, daily administration of CGS21680,
an A2A adenosine receptor-selective agonist, improved the motor
performance, prevented a reduction of brain weight, and normal-
ized elevated blood glucose levels in the R6/2 mouse. It also signif-





reto prevent the decrease of the NAA/tCr ratio [13]. Neuroprotective
effects of creatine were observed in N171-82Q and R6/2 animals.
Dietary creatine supplementation not only significantly increased
brain tCr concentrations and delayed decreases in NAA, but also
improved survival, slowed down the development of brain atro-
phy, reduced the formation of intranuclear inclusions, and delayed
the development of hyperglycemia. These results suggest a meta-
bolic dysfunction in Huntington’s disease which may benefit from
therapeutic strategies that strengthen the energy metabolism in
order to delay the pathologic process [6].
It has been noted that the neurochemical profile in the striatum
of R6/2 mice is rather distinct from those found in non-transgenic
animal models of Huntington’s disease [28]. For example, differ-
ences exist in comparison to the quinolinic acid rat model [73]
and the 3-nitropropionic (3NP) acid monkey model [115]. A clari-
fication of these findings requires further studies in different spe-
cies but may open additional insights into progression and
treatment of Huntington’s disease.
3.6. Alzheimer’s disease
Alzheimer’s disease is an age-dependent neurodegenerative dis-
order that leads to a progressive decline of cognitive functions.
Neuropathological hallmarks of Alzheimer’s disease are amyloid pla-
ques andneurofibrillary tangles in the central nervous system. So far,
an unambiguous diagnosis is only possible postmortem. Because the
increased life span is expectedtodramatically enhance thenumberof
affected patients, there is an urgent need for a surrogatemarker that
allows for an in vivo diagnosis of Alzheimer’s disease. Even more
importantly, such amarkerwouldbea valuable tool in thepreclinical
evaluation of new drugs and, subsequently, for the assessment of
treatment efficacy in individual patients. The neurochemical abnor-
malities of Alzheimer’s disease have been studied by proton MRS in
different transgenic mouse models [11,17,18].
A first study [11] employed transgenic mice which express mu-
tant forms of human amyloid precursor protein (APPTg2576). APP
mice develop b-amyloid plaques throughout the cortex starting
at 10 months of age. Though statistically not significant, proton
ig. 11. Transgenic mouse model of guanidinoacetate methyltransferase (GAMT)
eficiency. Localized proton MRS (7.0 T, STEAM, TR/TE = 5000/10 ms,
 3 3 mm3, 64 accumulations) of the brain of a guanidinoacetate methyltrans-
rase-deficient (GAMT/) mouse demonstrates a dramatic loss in tCr (arrows)
elative to a wild-type (WT) animal. Adapted from Ref. [9] with permission.
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and Tau/tCr intensity ratios at 19 months. In comparison to wild-
type mice, in vitro NMR spectroscopy of APP mice demonstrated
significant decreases of the NAA/tCr and Glu/tCr ratios and an in-
crease of the Tau/tCr ratio, while the Ins/tCr ratio remained normal.
Although elevation of Ins has been proposed as an early indicator
of Alzheimer’s disease in humans, this finding could not be
confirmed.
In a second model of Alzheimer’s disease [17] mice express mu-
tant forms of human presenilin 2 (PS2) and APP (PS2APP). PS2APP
mice develop severe amyloidosis in the neocortex including the
hippocampus at 8 months of age. Serial proton MRS throughout
the life span revealed stable NAA/tCr and Glu/tCr ratios during
the first 12 months of age, but significantly decreased NAA/tCr
and Glu/tCr ratios in 24-month-old animals. In line with the afore-
mentioned study of Alzheimer’s disease [11], differences of the Ins/
tCr ratio were not detected.
A third study [18] used mice which coexpress mutant human
presenilin 1 (PS1) and amyloid-b precursor protein (APP-PS1).
Amyloid plaques start to appear at 3 months of age. Again, proton
MRS of APP-PS1 mice at 16–23 months revealed reduced NAA/tCr
and Glu/tCr ratios with advanced age. In contrast to the former
studies [11,17], this model also caused a strong increase of the
Ins/tCr ratio as shown in Fig. 10. Because APP-PS1 mice develop
plaques at a faster rate than APP mice, it cannot be excluded that
APP mice with the same plaque load as found in 20-month-old
APP-PS1 mice would also lead to elevated Ins/tCr ratios. Further re-
search is needed to determine whether plaque load or genotype
are responsible for an increased Ins/tCr ratio.
Interestingly, age-dependent changes of the cerebral metabolite
profile observed in APP-PS1 mice closely resemble proton MRS re-
sults obtained in patients with probable Alzheimer’s disease, e.g.,
see [260]. Although still a matter of controversy, the transgenic
APP-PS1 mouse model seems to best match the neurochemical
profile found in humans.
3.7. Deficiencies of energy metabolism
In vivo MRS studies of transgenic mouse models with altered
high-energy phosphoryl transfer metabolism have recently been
reviewed [180]. A prominent example is a knockout mouse model
of guanidinoacetate methyltransferase (GAMT) deficiency. This
phenotype had originally been discovered as ‘‘creatine deficiency”
by in vivo proton MRS of a human patient [261,262]. As demon-Fig. 10. Transgenic mouse model of Alzheimer’s disease. Localized proton MRS (9.4 T, LA
which coexpresses mutated human presenilin 1 and amyloid-b precursor protein (AP
comparison to an age-matched wild-type (WT) animal, the old APP-PS1 mouse exhibits




rstrated in Fig. 11, GAMT-deficient mice indeed suffer from mark-
edly reduced brain tCr levels [9]. By combining in vivo and
in vitro phosphorus and proton MRS of brain and muscle tissue it
could be demonstrated that GAMT-deficient mice present with
similar abnormalities as those found in human GAMT deficiency
patients. The model therefore emerges as a valid tool for further
investigations of the biosynthesis and intracellular transport of
creatine. For example, a longitudinal study of creatine supplemen-
tation in GAMT-deficient mice indicated that creatine uptake is fas-
ter in skeletal muscle than in brain [29].
Another important enzyme for oxidative phosphorylation is
creatine kinase (CK). Transgenic mice that lack either the cytosolic
isoenzyme (B-CK/) or the mitochondrial ubiquitous isoenzymeSER, TR/TE = 3000/28 ms, 18 ll, 192 accumulations) of the brain of a mouse (B6/SJL)
P-PS1) at 16, 20, and 23 months of age. When scaled to tCr (dotted line) and in
decreased NAA/tCr and Glu/tCr ratios as well as an increased Ins/tCr ratio (arrows).
Fig. 12. Transgenic mouse model of Rett syndrome. Localized proton MRS (4.7 T,
PRESS, TR/TE = 1500/16 ms, 3:5 3:5 3:5 mm3, 256 accumulations) of the brain of
a Mecp2/y mouse shows decreased Ins and increased Tau resonances (arrows)
relative to a control. Metabolite ratios with the sum of all metabolite signals reveal
increased NAA/sum and decreased Glx/sum and Ins/sum ratios in Mecp2/y mice
(arrows). Adapted from Ref. [26] with permission.
Fig. 13. Transgenic mouse model of Down syndrome. Localized proton MRS (4.7 T,
STEAM, TR/TE = 1500/30 ms, 5 3 5 mm3, 512 accumulations) of the brain of a
Ts65Dn mouse reveals a decreased NAA/tCr and increased Ins/tCr ratio (arrows) in
comparison to a control. Adapted from Ref. [4] with permission.
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phosphate (ATP) as well as tCr and NAA as revealed by phosphorus
and proton MRS, respectively [10]. In contrast, however, double
knockouts (CK/) presented with extremely low PCr concentra-
tions below detectability but otherwise normal high-energy phos-
phates [10]. Proton MRS of these animals detected a 20–30%
decrease of tCr and a similar increase of NAA in all brain regions
investigated. Both alterations are unexpected and raise new ques-
tions about physiological roles of tCr other than a mere function in
energy metabolism. Similar arguments hold true for NAA. While
elevated NAA levels may reflect alterations of its concentration in
neurons and/or differences in the relative neuronal volume due
to changes in cell size and/or cell type distribution, it has also been
suggested that a concomitant NAA increase and tCr decrease may
reflect a redistribution of cerebral osmolites [10]. These studies
clearly point to the powerful role of mice in unravelling the genetic
control of basic (and disturbed) in vivo physiology.
3.8. Transgenic models of other diseases
Amytrophic lateral sclerosis (ALS) is a severe neurodegenerative
disease characterized by motor neuron loss. Transgenic mice with
the G93A human superoxide dismutase mutation were proposed
as an animal model of familial ALS. G93A mice develop progressive
motor weakness starting at about 100 days of age. Rapid disease
progression results in premature death after about 1 month. Proton
MRS revealed increased Glx/tCr ratios in G93Amice brain at 80 and
115 days of age [7]. However, alterations of the NAA/tCr and Cho/
tCr ratios were statistically not significant. Creatine supplementa-
tion, starting at 4 weeks of age, significantly increased longevity
and motor performance and attenuated the increases of the Glx/
tCr ratio at 80 days of age, but had no effect at 115 days of age
[7]. The results are consistent with impaired Glu transport in the
brain of G93A mice.
Rett syndrome is an X-linked neurologic disorder in which most
patients carry a mutation in the gene encoding the methyl-CpG-
binding protein 2 (MECP2). Proton MRS in Mecp2/y mice with a
complete absence of the Mecp2 gene product in all cells revealed
decreased ratios of Glx and Ins with the sum of all other metabolite
resonance areas as well as an increased NAA/sum ratio [26]. These
ratios are not generally accepted and may mask a disturbance
depending on other changes of individual metabolites. In fact, vi-
sual inspection of the spectra shown in Fig. 12 does not support
the conclusion of a significant change in the NAA/tCr and Glx/tCr
ratio. A proton MRS study of 9 girls with Rett syndrome in the
age range 2–21 years reported a mild decrease of absolute NAA lev-
els with increasing age but revealed no other abnormalities [263].
Canavan disease is another rare neurological disorder, classified
as leukodystrophy, where clinical symptoms such as mental retar-
dation, abnormal muscle tone, and abnormal head size appear in
early infancy and progress rapidly. The underlying genetic defect
is an aspartoacyclase deficiency which normally breaks down
NAA. Loss of the enzyme increases the cellular concentration of
NAA as shown by proton MRS of affected children [264] and im-
pairs the normal function of the nervous system. A proton MRS
study of a respective knockout mouse revealed a dramatic increase
of the NAA/tCr ratio in the thalamus of homozygous mice relative
to wild-type and heterozygous animals [5]. These results were con-
firmed by high-resolution proton NMR spectroscopy of brain ex-
tracts and suggest the successful creation of a mouse model of
Canavan disease for further evaluation.
The segmental trisomy Ts65Dn mouse serves as a model of
Down syndrome which is a genetic disorder caused by abnormal
cell division during development. In humans, Down syndrome or
trisomy 21 is characterized by three (instead of two) copies of
chromosome 21 and leads to mental retardation and other prob-lems with largely variable severity. A proton MRS study reported
decreased NAA/tCr and elevated Ins/tCr ratios in Ts65Dn mice
[4]. Although this finding is in line with results reported in patients
[265], the achieved spectral quality shown in Fig. 13 precludes a
reliable evaluation of the Ins resonance. Despite this difficulty
the study reported a decreased Ins/tCr ratio for the combined
group of controls and Ts65Dn mice after 30 days of lithium treat-
ment, while the NAA/tCr and Cho/tCr ratios remained unaltered
[4]. Further investigations are needed to confirm these preliminary
results.
Fig. 14. Identification of glucose in rat brain in vivo. Localized proton MRS (2.35 T,
STEAM, TR/TE = 3000/20 ms, 5 5 5 mm3, 128 accumulations) of rat brain in vivo
and 25 min postmortem allow for the assignment of the strongly coupled
resonances at 3.43 ppm (overlap with Tau) and 3.8 ppm (overlap with a-CH
resonances of Glx) to Glc. The in vivo resonances vanish due to nonoxidative
glucose consumption during early postmortem phases, while the weakly coupled
doublet resonances at 1.33 ppm indicate the resulting accumulation of Lac. Adapted
from Ref. [32] with permission.
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The human immunodeficiency virus (HIV) attacks specific white
blood cells that form an important part of the immune system.
After about a decade of progressively reducing the effectiveness
of the immune system, HIV infections lead to the acquired immune
deficiency syndrome (AIDS) which leaves individuals susceptible
to a large variety of opportunistic infections and tumors. In order
to generate a mouse model of HIV-1 encephalitis, human HIV-in-
fected monocyte-derived macrophages were unilaterally injected
into the subcortex of immunodeficient mice. The procedure yields
focal giant cell encephalitis, reactive astrocytes, microgliosis, and
neuronal dropout 7 days after injection as confirmed by histology
[16]. In comparison with unmanipulated and sham-operated ani-
mals proton MRS of HIV-1 encephalitis mice exhibited a significant
NAA reduction in both the injected and contralateral hemisphere
as well as in subregions such as the hippocampus, where neuropa-
thology was limited or absent. A group average of all spectra from
all animals revealed a statistically significant, global decrease of
the NAA concentration. Because concomitant global alterations of
the Cho and tCr concentrations were not observed, the NAA reduc-
tion may not be explained by edema or enlarged cerebrospinal
fluid (CSF) spaces. The data suggest that a highly focal encephalitis
can produce global deficits in neuronal function and metabolism
[16].
3.10. Prion diseases
The infectious agent in a prion disease is a protein, usually a
normal cell membrane protein with an atypical three-dimensional
configuration. Prion diseases such as the human Creutzfeldt–Jakob
disease, scrapie in sheep and goats, and the bovine spongiform
encephalopathy (BSE) or ‘‘mad cow disease” are usually referred
to as transmissible spongiform encephalopathies. They lead to
extensive vacuole formation in the central nervous system, devel-
op progressively, and are all fatal. Proton MRS of mouse models of
prion diseases discovered alterations of cerebral metabolite levels
already in early preclinical stages [25]. Adult C57BL/6 mice were
inoculated intracerebrally with either the mouse-adapted BSE
strain 6PB1 or the mouse C506M3 scrapie strain and followed up
to 180 days post infection. Interestingly, in BSE-infected mice the
increase of the Ins/tCr ratio preceded clinical signs such as ataxia
by 20 days and was followed by a decrease of the NAA/tCr ratio
at advanced stages. In scrapie-infected mice, changes of the NAA/
tCr and Ins/tCr ratios were detected at the beginning of the symp-
tomatic phase. Because the incubation period was shorter in the
scrapie model and because the first MRS examination was per-
formed too late to detect preclinical alterations, an early increase
of the Ins/tCr might have been missed due to study design [25].
However, in either case decreased NAA/tCr ratios are in line with
observations in a further murine ME7 model that support the view
that NAA/tCr reductions precede clinical signs and occur concomi-
tant with early behavioral deficits [30]. These findings could allow
for an early investigation of pathological alterations in prion dis-
eases using in vivo MRS.
4. Rat models
Rats are common laboratory animals in preclinical brain re-
search offering a broad variety of disease models. Rats were also
the first animals in 1983 to be investigated by (nonlocalized) pro-
ton MRS in vivo [191–195]. These early studies dealt with technical
feasibilities but also addressed normal and pathological brain
metabolism in vivo and in utero. To date, rats are still the most fre-
quently used animals for localized proton MRS of brain metabo-
lism. Because the large number of studies precludes acomprehensive survey, this section will focus on a selection of
important in vivo applications.
4.1. Normal physiology
Initial applications of localized proton MRS to normal rat brain
identified metabolite resonances at short echo times and studied
their alterations shortly after death [31]. As depicted in Fig. 14 such
studies for the first time demonstrated access to cerebral glucose
(Glc) concentrations in vivo [32]. At 2.35 T the strongly coupled
Glc resonances merge into two apparent singlets at 3.43 and
3.8 ppm that overlap with the multiplet resonances of Tau and
the a-CH resonances from Glu and Gln, respectively. After death
Glc vanishes due to temporary nonoxidative glucose consumption
(from free Glc as well as brain glycogen stores) and causes a con-
comitant accumulation of Lac in the absence of blood flow.
While early rat brain studies relied on metabolite ratios to tCr,
the adaptation of user-independent quantification methods to sur-
face coil studies led to numerous reports of absolute metabolite
concentrations. For example, using ultra-short echo times of
TE = 1–2 ms, quantification of high-field MRS acquisitions involved
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chemical profiles of the hippocampus, striatum, and cortex are
most pronounced for NAA, Cho, Tau, and Ins [79]. A comparison
of low-field versus high-field proton MRS of rat brain as shown
in Fig. 15 confirms the findings reported for mice: because the
achievable resonance linewidths are smaller at low fields (about
7 Hz [31]) than at high fields (about 12 Hz [60]), the full realization
of the high-field advantages strongly depends on the ability to im-
prove the local magnetic field homogeneity. T1 and T2 relaxation
times of major metabolites in rat brain have been determined at
4.0, 9.4, and 11.7 T [97].
When studied as a function of postnatal age, proton MRS of rat
brain revealed marked changes in cerebral metabolite composition
in the hippocampus, striatum, and cortex during early develop-
ment [79]. This particularly applies to increases of NAA, Glu, tCr,
and Ins as well as to decreases of Tau and Cho in all investigated
brain regions. The effects are clearly visible in Fig. 16 for the hippo-
campus. In general, the in vivo metabolite concentrations for dif-
ferent ages and/or brain regions are in agreement with values
obtained by in vitro proton NMR spectroscopy of tissue extracts
[266–268].
Cerebral metabolite changes in response to functional brain
activation have been studied by proton MRS of a-chloralose-anes-
thetized rats [96] as demonstrated in Fig. 17. During forepaw stim-Fig. 15. Localized proton MRS of rat brain in vivo at different field strengths. In comparis
accumulations) the use of a high field (9.4 T, STEAM, TR/TE = 4000/1 ms, 4 4 4 mm3, 3
and Ins are more easily identified at 2.35 T (compare Fig. 5 for mouse brain). Note tha
resonances at 3.9 ppm. Other detectable resonances refer to tNAA, tCr, Cho, and Ins as welulation and concomitant focal activation of the primary
somatosensory cortex, the main observation was a decrease of
the PCr/Cr ratio (resolved in high-field proton MR spectra), but
no elevation of Lac – the latter finding is in line with similar obser-
vations in cats [136]. These results suggest that increased energy
consumption due to focal brain activation causes a shift in the cre-
atine kinase reaction towards the direction of ATP production, that
is at the expense of reduced PCr and correspondingly elevated Cr
[96]. At the same time, the enhanced energy demand does not lead
to a significant increase in the glycolytic lactate production under
physiological conditions.
4.2. Cerebral ischemia and hypoxia
During the past two decades rats have served as key animals for
studies of global or focal cerebral ischemia, for reviews see
[169,173,175,176]. Apart from histological correlations, proton
MRS in vivo is often combined with other techniques such as diffu-
sion-weighted MRI or electrophysiological recordings of transient
cell depolarization [36,39]. For quantitative assessments of metab-
olite concentrations it is important to note that in the ischemic re-
gion T1 and T2 relaxation times of the metabolites NAA, tCr, and
Cho were found to remain unchanged during the first few hours
of ischemia but altered after 24 h [40].on to low field acquisitions (2.35 T, STEAM, TR/TE = 6000/20 ms, 7 5 7 mm3, 304
20 accumulations) leads to a better identification of Glu, Gln, and Tau, whereas Glc
t the high field allows for a separation of creatine (Cr) and phosphocreatine (PCr)
l as MM, Lac, Ala, GABA, NAAG, and Asp. Adapted from Refs. [61,62] with permission.
Fig. 16. Rat brain in vivo during maturation. Localized proton MRS (9.4 T, STEAM, TR/TE = 5000/2 ms, 11–18 ll, 320 accumulations) of the hippocampus as a function of
postnatal age (days 7–28) demonstrates an increase of NAA, Glu, tCr, and Ins as well as a decrease of Cho and Tau during early development (compare Fig. 6 for mouse brain
maturation). Adapted from Ref. [79] with permission.
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10 min of transient global ischemia in rats revealed a rapid decline
of brain Glc and a corresponding increase of Lac [41]. During reper-
fusion Lac clearance was characterized by a first-order rate con-
stant of 0.03/min. The recovery of Glc above basal concentrations
within 1 h after the end of ischemia suggests a transient mismatch
of Glc uptake and consumption during the early post-ischemic
phase. Moreover, while NAA, tCr, Cho, and Ins concentrations re-
mained constant during early reperfusion, NAA and tCr levels de-
creased several hours later. After 24 h of reperfusion most
metabolite concentrations were found to be severely reduced
[51]. In models of focal cerebral ischemia that involve a permanent
occlusion of the middle cerebral artery, a continuous decrease of
NAA was seen starting after the onset of ischemia [39,42,56].
Oral supplementation of creatine has been proposed to possess
neuroprotective potential. In rats dietary creatine resulted in ele-
vated cerebral concentrations of tCr and Ins as determined
in vitro, while in vivo proton MRS revealed only trends for elevatedtCr, Ins, and Glc [62]. The concomitant observation of a statistically
significant decrease of cerebral Lac in creatine-fed rats indicated a
strengthening of the oxidative metabolism relative to nonoxidative
glycolysis. However, when comparing creatine-fed rats and con-
trols during ischemia and early reperfusion, Fig. 18 demonstrates
no differences with respect to Lac accumulation and clearance as
well as Glc depletion and recovery. To further assess the therapeu-
tic potential of creatine supplementation, mean time courses of the
trace of the brain water apparent diffusion coefficients (ADC) were
acquired [63]. During ischemia the observed decrease of the ADC
trace in three stages paralleled the sequential pathophysiological
events of energy depletion, development of a cytotoxic edema,
and brain cooling. But again, less severe and mildly delayed diffu-
sion changes in creatine-fed rats during ischemia and similar ben-
eficial trends during early reperfusion did not reach statistical
significance [63].
Other studies investigated therapeutic options at later stages of
ischemia. For example, proton MRS was used to demonstrate that
Fig. 17. Rat brain in vivo during functional activation. Localized proton MRS (11.7 T, LASER, TR/TE = 5000/15 ms, 3:5 2:0 4:5 mm3, 128 accumulations) of primary
somatosensory cortex during forepaw stimulation and motor rest reveals a decreased PCr/Cr ratio in the stimulated state but no alteration of Lac (see zoomed inserts).
Adapted from Ref. [96] with permission.
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cells protect against ischemic injury [98]. About one week after fo-
cal ischemia untreated rats revealed the expected focal NAA de-
creases and Lac increases in the lesion, whereas rats treated 12 h
after ischemia exhibited a normal NAA/tCr ratio and low Lac levels.
These findings suggest at least a partial preservation of brain tissue
in response to stem cell transplantation [98].
Diffusion-weighted MRI provides a sensitive tool for imaging af-
fected tissue during acute stroke. Complementary, diffusion-
weighted MRS [166] has been used to monitor alterations of intra-
cellular metabolite diffusion in rat brain during transient global
ischemia and reperfusion [43] as well as during focal ischemia
[49,71]. The ADCs of NAA, tCr, Cho, and Ins decrease during ische-
mia. As shown in Fig. 19 the corresponding increase of the diffu-
sion-weighted MRS signal intensity is more pronounced for the
glial marker Ins than for the neuronal marker NAA, indicating dis-
tinct glial responses to ischemia. These results are contradictory to
the naive assumption that an increased intracellular volume due to
the development of cytotoxic edema should increase rather than
decrease the ADC of metabolites. In fact, neither changes of the
metabolite concentrations [41] nor metabolite T2 relaxation times
[55] were observed during and shortly after transient global ische-
mia which excludes changes in intracellular viscosity. Reduced
metabolite ADCs are more likely to reflect the failure of ATP-
dependent transport processes that contribute to the intracellular
streaming under normal physiological conditions. While furtherstudies are warranted, the approach provides a novel basis for
the assessment of circulatory and metabolic compromise during
ischemia and reperfusion.
In contrast to ischemia, cerebral hypoxia refers to a deficiency
of oxygen supply to the brain in the presence of adequate blood
flow. In humans, this may be caused by drowning, strangling, suf-
focation, carbon monoxide poisoning, and complications of general
anesthesia. The effects of chronic hypoxia on the developing brain
have been studied by proton MRS in a rat model of continuous hy-
poxia from postnatal days P3 to P28 [94]. Although the age-depen-
dent metabolite profiles found in the hippocampus of affected rats
were qualitatively similar to those seen in normoxic animals, sev-
eral metabolites did not reach normal concentrations. The observa-
tion of an increased PCr/Cr ratio was proposed to be consistent
with a decreased energy consumption in the brain. The elevated
GABA level was taken as an indicator of suppressed excitatory neu-
rotransmission in an energy-limited environment, while decreased
NAA was suggested to reflect reduced neuronal integrity.
4.3. Multiple sclerosis
A rat model of experimental demyelination employed intracere-
bral injections of lysophosphatidylcholine (LPC) to induce focal
brain lesions [76]. Histology demonstrated demyelination around
the site of injection with surrounding edema and prominent infil-
tration of inflammatory cells in the early phase. After about 2
Fig. 18. Rat model of transient global cerebral ischemia (hashed bar) yielding mean
time courses of Lac and Glc concentrations (in mM) for creatine-fed rats (n = 6,
closed squares) and controls (n = 7, open squares). Localized proton MRS (2.35 T,
STEAM, TR/TE = 6000/20 ms, 7 5 7 mm3, 16 accumulations) at a temporal
resolution of 96 s reveals Glc depletion and recovery as well as Lac accumulation
and clearance, but no differences between groups. Adapted from Ref. [62] with
permission.
ig. 19. Rat model of transient global cerebral ischemia (hashed bar) yielding mean
me courses of diffusion-weighted MRS signal intensity changes of water and
etabolite resonances (n = 8). Localized proton MRS (2.35 T, STEAM, TRP 3000 ms
espiratory triggered, TE = 120 ms, 7:5 5:0 7:5 mm3, 64 accumulations) was
erformed with diffusion gradients in both TE/2 intervals (D ¼ d ¼ 25 ms) yielding
= 2960 s mm2. Signal increases correspond to a decrease of the apparent
iffusion coefficient. Adapted from Ref. [43] with permission.
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trast to EAE models of multiple sclerosis that predominantly cause
spinal cord lesions, LPC-induced lesions have a precise location and
therefore offer sequential follow-up proton MRS studies even prior
to full lesion development. In fact, early demyelination was charac-
terized by decreased NAA/tCr ratios, increased Cho/tCr ratios, and
elevated lipid and/or macromolecular signals in the internal cap-
sule [76]. With the onset of remyelination, these alterations were
reversed and the metabolite ratios recovered to normal values.
Further correlative studies with histology are needed to establish
more specific markers than a metabolite ratio that may serve for
a better differentiation of acute and chronic lesions as well as of
demyelination versus remyelination.
4.4. Parkinson’s disease
Only a few proton MRS studies have addressed Parkinson’s dis-
ease in rats. As for mice, intoxication of brain tissue after intrastri-
atal injections of MPTP led to acute and focal increases of Lac with
normal levels of NAA [46]. One week after the injection Lac levels
returned to baseline and NAA decreased. A further decline of NAA
was observed up to 3 months post injection. The results are in line
with similar observations in mice [15,24] and monkeys [114].
4.5. Huntington’s disease
Several proton MRS studies of rat brain revealed metabolic
alterations in different models of Huntington’s disease. Intrastria-
tal injections of the N-methyl-D-aspartate (NMDA) agonist quino-






dmitochondrial toxin 3NP [46,57,66,67,90,116] were used to induce
selective striatal lesions. The axon-sparing excitotoxic quinolinic
acid causes neuronal damage by overstimulation of glutamate
ig. 20. Rat model of Huntington’s disease. Localized proton MRS (4.7 T, PRESS, TR/
E = 2000/135 ms, 5 5 5 mm3, 256 accumulations) of rat striatum after 3NP
toxication shows increased Lac and succinate (Suc) relative to sham-operated
nimals. These alterations were markedly reduced after pre-treatment with
motrigine at a dose of 10 (Lam10) or 20 mg/kg/day (Lam20) or with MK-801.
dapted from Ref. [67] with permission.
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tion of nitric oxide and other free radicals. The model produces
behavioral and neuroanatomical effects which closely mimic some
of the characteristics of Huntington’s disease. Proton MRSI re-
vealed dose-dependent decreases of NAA, tCr, and Cho two weeks
after injection of quinolinic acid, consistent with a generalized loss
of viable cells in the striatum [52]. Five days after a relatively low
dose of quinolinic acid, quantitative proton MRS revealed striatal
increases of Gln in conjunction with decreased NAA, Glu, Tau,
and tCr [73]. At higher doses, quinolinic acid resulted in more pro-
nounced changes consistent with necrosis.
The primary effect of 3NP is the partial blockade of mitochon-
drial complex II including the inhibition of succinate dehydroge-
nase. Acute metabolic changes after 3NP administration were
reported to be time-dependent and partly reversible. In particular,
3 h after a single 3NP administration, proton MRS demonstrated a
simultaneous increase of the ratios of Suc/tCr and acetate/tCr.
These changes were followed by elevated Lac and later also re-
duced NAA. After depletion of NAA, acetate decreased to baseline
levels suggesting hydrolysis [66]. It is of general interest for the
interpretation of NAA changes that the reversible reduction of
NAA in the acute phase indicates reversible mitochondrial dysfunc-
tion rather than neuronal loss [90,116]. In final stages, however,
neuronal cell death was observed if 3NP administration was con-
tinued. Accordingly, studies of symptomatic rats at 4 weeks and
4 months after administration showed no Suc and Lac but in-
creased Cho/tCr and decreased NAA/tCr ratios [90].
The efficacy of neuroprotective interventions in rats after 3NP-
induced striatal lesioning was investigated using creatine and cycl-
ocreatine [57] as well as lamotrigine and dizocilpine maleate (MK-
801) [67]. Oral supplementation of creatine but not of cyclocrea-
tine protected against 3NP neurotoxicity as indicated by smaller le-
sion volumes and reduced Lac/NAA ratios in the acute phase [57].
Creatine supplementation increased cerebral PCr concentrations
and therefore alleviates the 3NP-induced depletion of the high-en-
ergy phosphate metabolites PCr and ATP. Alternative treatment
strategies addressed the excitotoxic brain injury in 3NP-treated
animals. Because it involves the activation of excitatory glutamate
receptors, excessive influx of calcium ions, and overproduction of
reactive oxygen species which together lead to cell death by apop-
tosis and necrosis, NMDA receptor antagonists such as MK-801
were considered as a therapeutic option [67]. In addition, applica-
tion of the anticonvulsant lamotrigine which modulates voltage-
gated calcium channels was proposed to counterbalance an over-
load of calcium ions in neurons [67]. As demonstrated in Fig. 20,
pre-treatment with either MK-801 or lamotrigine indeed pre-
cluded the common increase of striatal Suc and Lac levels after
3NP-induced lesioning and mostly prevented decreases of the
NAA/tCr and Cho/tCr ratios [67]. These results suggest considerable
potential of localized proton MRS for monitoring therapeutic inter-
ventions in Huntington’s disease.
4.6. Hydrocephalus and head trauma
Hydrocephalus arises from abnormal accumulation of CSF in the
ventricles of the brain. It causes increased intracranial pressure and
progressive enlargement of the head, convulsion, and mental dis-
ability. The condition may result from an overproduction of CSF,
from a congenital malformation blocking normal CSF outflow, or
from complications of head injuries or infections. The use of local-
ized proton MRS for an evaluation of cerebral metabolism in
hydrocephalus has recently been reviewed [171]. Rat studies have
been combined with T2-weighted MRI, diffusion-weighted MRI,
and phosphorus MRS [54,59,65].
Rat models of hydrocephalus involve injection of kaolin into the





Astrongly enlarged ventricles 16 weeks after intoxication. Proton
MRS of a relatively large VOI detected elevated Lac at all time
points investigated, while MRSI identified Lac to be mainly present
in CSF [59]. The observation of decreased NAA/Cho and Cho/tCr ra-
tios was suggested to implicate neuronal loss/dysfunction or
changes in membrane phospholipid metabolism [65].
In humans, concussion is the most common and least serious
type of traumatic brain injury. However, a head trauma can also
lead to epidural and subdural hematoma, subarachnoid hemor-
rhage, cerebral contusion, and diffuse axonal injury. In many cases,
these alterations are accompanied by increased intracranial pres-
sure which then becomes the main goal of treatment. In a rat mod-
el of experimental traumatic brain contusion metabolic changes
were followed for up to 4 weeks by proton MRS and histology
[83]. Immediately after lesioning pericontusional concentrations
of NAA, tCr, and Glu decreased due to neuronal cell disintegration
and other secondary perturbations unraveled by histology. Metab-
olite concentrations partially recovered at day 7 in parallel to
immunohistochemical indications of repair, but without regaining
control levels at day 28. Though initially decreased, the concentra-
Fig. 21. Rat model of hydrocephalus. Localized proton MRSI (4.7 T, PRESS, TR/
TE = 2500/244 ms, 2 2 4 mm3, 16 16 acquisition matrix) of the brain 8 weeks
after kaolin injection reveals elevated Lac predominantly in CSF. Adapted from Ref.
[59] with permission.
ig. 22. Rat model of brain tumor. Localized proton MRS (2.35 T, STEAM, TR/
E = 3000/20 ms, 4 4 4 mm3, 256 accumulations) of three different animals 2
eeks after inoculation of F98 glioma cells into the right caudate nucleus
emonstrates pronounced interindividual variability of the growing tumors. This
articularly applies to the concentrations of Lac and mobile lipids (0.9, 1.3, and
.05 ppm). Adapted from Ref. [33] with permission.
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cating glial activation and proliferation. Increased levels of Lac and
lipids were detected at all time points [83].
Another rat study examined whether proton MRS is capable of
measuring S100B proteins which are released by astrocytes after
lateral fluid-percussion injury and thought to correlate with out-
come [93]. The in vitro identification of a S100B resonance at
4.5 ppm was based on a positive correlation between different
S100B concentrations and the resonance integral as well as by an
increased resonance in rat brain in vivo after 5 days of continuous
intraventricular infusion of S100B [93]. It should be mentioned,
however, that the unambiguous analysis of a resonance close to
that of brain water is extremely difficult under in vivo conditions,
mainly because of the distorted lineshape of the residual water-
suppressed signal.
4.7. Primary brain tumors
The growth of intracranial tumors is caused by the uncontrolled
proliferation of cells. Brain neoplasms are subdivided into primary
tumors that originate from glia such as astrocytes (astrocytomas),
oligodendrocytes (oligodendrogliomas), or ependymal cells (epen-
dymoma) and secondary tumors that represent metastatic forms.
Proton MRS was performed to enhance the diagnostic specificity
of MRI procedures and, in animals, to study tumor metabolism
for a better understanding and optimization of therapeutic inter-
ventions. For a review about tumor metabolomics in animal mod-
els of human cancer see [179]. The studies discussed here
employed intracerebral gliomas grown after in vivo implantation
of C6 cells [38,72,81], F98 cells [33], RT2 cells [37], 9L cells [44],
or BT4C cells transfected with a viral herpes simplex virus thymi-
dine kinase (HSV-tk) gene [64,80].
In comparison to normal contralateral brain tissue and notwith-
standing technical differences such as echo times and VOI sizes,
proton MRS studies of gliomas generally yield (i) strongly in-
creased Lac and/or lipids, (ii) reduced or even depleted NAA, de-
creased tCr, strongly increased Cho, and elevated Ins with
potential contributions from glycine. Fig. 22 illustrates the high de-
gree of interindividual variability found in F98 gliomas which ham-
pers the establishment of a consistent relationship between proton
MRS observations and tumor development [33]. Part of the vari-
ability can be explained by the heterogeneity of the tumor tissue
which is also supported by proton MRSI of C6 gliomas demonstrat-
ing differences in the spatial distribution of metabolites [38,72,81].





2at later stages of tumor development and mainly arise from lipid
droplets in necrotic areas [81]. After the infusion of 2-imidazole-
1-yl-3-ethoxycarbonylpropionic acid (IEPA) into the right jugular
vein, IEPA resonances were detected only in the glioma and en-
abled the calculation of a mean extracellular pH of 7.08 from the
chemical shift of the pH-dependent H2 resonance [72]. NAA and
Lac levels were found to correlate negatively with MRS-detected
IEPA level, as expected for a glioma surrounded by normal tissue.
However, the unexpected lack of a negative correlation of Lac with
extracellular pH led to the conclusion that Lac production is great-
est in well-perfused parts of gliomas from which proton equiva-
lents are rapidly cleared [72].
In a rat model of intracranial 9L glioma, proton MRS was applied
to assess the efficacy of gene therapy [44]. The treatment involved
ig. 23. Rat model of epilepsy. Localized proton MRS (4.7 T, PRESS, TR/TE = 2500/
35 ms, 10  3:4 3:6 mm3, 768 accumulations) of rat hippocampus after kainic
cid-induced seizures shows increased Lac in the acute phase and decreased NAA at
ter stages. Adapted from Ref. [53] with permission.
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tumor and a subsequent systemic administration of the antiherp-
etic agent ganciclovir. MRI of treated rats revealed a significant
reduction of the doubling time for tumor volume, but with a large
variation in antitumor activity of individual animals. Proton MRS of
untreated gliomas exhibited reduced NAA and tCr levels but no
other changes as compared to normal tissue in the contralateral
hemisphere. In contrast, treated tumors exhibited dramatic in-
creases of resonances in the 0.9–1.3 ppm range from mobile lipids
and/or Lac. The results suggest that specific changes of the tumor
metabolite profile may be predictive of the effectiveness of the ap-
plied therapeutic regimen [44].
Other studies used BT4C glioma cells that were transfected with
the viral HSV-tk gene and implanted into the corpus callosum
[64,80]. In contrast to the aforementioned work [44], proton MRS
of the solid tumor was dominated by resonances from saturated
lipids (1.3 ppm) and polyunsaturated fatty acids (5.4 ppm). Altera-
tions of these lipids as well as of tCr, Glx, Cho, Tau, and Ins (plus
glycine) were quantified during days 0–8 of ganciclovir treatment.
The histologically determined decrease of tumor cell density with
treatment was paralleled by decreases of tCr, Tau, and Ins (glycine)
as well as by increases of saturated and unsaturated lipids. The
authors concluded that increases of saturated and unsaturated lip-
ids can be used as a marker for tumor growth arrest and early
detection of tumor eradication in vivo.
4.8. Epilepsy
Epilepsy is a chronic neurological disorder characterized by
recurrent unprovoked seizures due to abnormal, excessive or syn-
chronous neuronal activity in the brain. In humans, temporal lobe
epilepsy is the most common variant in adults with involvement of
the hippocampus. Although still an open question whether or not it
is a cause or an effect of seizures, hippocampal sclerosis seems to
represent a common pathological pathway to partial epilepsy from
a number of different causes.
Proton MRS studies of the hippocampus have assessed the
metabolite profiles during and after seizures. In most cases status
epilepticus was induced by systemic administration of kainate acid
[53,58] or pilocarpine [82,91]. The data constitute a rather consis-
tent picture of hippocampal alterations in epileptic rats. As demon-
strated in Fig. 23, elevated Lac is usually detected as early as 1 h
after seizure onset [53,91] and persists for up to 7 days while
slowly decreasing toward normal levels [53]. Moreover, and apart
from a report about transient increases of the NAA/tCr ratio in the
acute phase [53], the NAA/tCr ratio is generally characterized by a
progressive reduction starting several hours after kainate adminis-
tration [53] or pilocarpine injection [82,91]. The Cho/tCr ratio in
these studies was either not altered [53,82] or decreased [91].
Pre-treatment with cycloheximide, a protein synthesis inhibi-
tor, prevented increases of the Lac/tCr ratio during and one day
after kainate-induced seizure onset [58]. Similar to an earlier study
[53], a transient increase of the NAA/tCr ratios was observed 1 h
after seizures which was not affected by the treatment [58]. How-
ever, one day after seizure onset, the NAA/tCr ratio in the hippo-
campus was higher in cycloheximide-treated animals than in
untreated rats. This indication of enhanced neuronal survival was
histologically confirmed by the absence of a significant cell loss
in both CA3 and hilar areas [58]. A separate study reported the
use of oral creatine to prevent the decrease of hippocampal NAA
28 days after pilocarpine injection [82]. Surprisingly, proton MRS
yielded normal NAA concentrations in creatine-fed epileptic rats,
whereas histology revealed an even more pronounced loss of pyra-
midal neurons than in untreated epileptic rats [82]. A plausible
explanation for the observation of normal NAA in the presence of
massive neuronal loss is still lacking.F
1
a
la4.9. Schizophrenia and depression
Schizophrenia denotes a complex syndrome of still relatively
unknown causes. Neurobiological investigations have demon-
strated an impaired function of the prefrontal cortex. In a rat model
of excitotoxic lesioning of the prefrontal cortex, proton MRS re-
vealed a persistent reduction of NAA in both prefrontal cortex
Fig. 24. Rat brain after electroconvulsive shock (ECS) treatment. Localized proton
MRS (4.7 T, PRESS, TR/TE = 2500/144 ms, 1:6 2:6 2:5 mm3, 256 accumulations)
of the hippocampus reveals an increased Cho/tCr ratio in response to treatment
(arrow). Adapted from Ref. [85] with permission.
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ronal integrity [70]. Similarly decreased NAA levels were observed
in the prefrontal cortex of young adult rats after neonatal excito-
toxic lesioning of the ventral hippocampus. The authors concluded
that early hippocampal lesions produce developmental neuronal
pathology in the prefrontal cortex that is associated with dysregu-
lation of dopamine behaviors and reminiscent of the temporal pro-
file of schizophrenia [77]. The effects of the antipsychotic drugs
haloperidol, clozapine, and olanzapine on metabolite ratios were
determined in normal rat brain and found to be negligible or ab-
sent [69]. In turn, these results suggest that the metabolite altera-
tions observed in treated schizophrenics reflect disease-related
disturbances rather than short-term effects of medication.
Major depressive disorder or simply depression is a mental dis-
order characterized by a pervasive low mood and diminished abil-
ity to experience pleasure. While there is no single known cause of
depression, it likely results from a combination of genetic, bio-
chemical, environmental, and psychological factors. Several proton
MRS studies evaluated the potential of electroconvulsive shock
(ECS) treatment in learned helplessness rats as an animal model
of depression [85,86]. As shown in Fig. 24, daily ECS treatment
led to elevated Cho/tCr and Cho/NAA ratios in the hippocampus
of normal rats, while the NAA/tCr ratio remained constant [85].
Thus, ECS-induced seizures seem to cause a different metabolic
profile than observed after kainate administration, where normal
Cho and reduced NAA levels have been reported. A concurrent
study demonstrated increased Cho/tCr ratios in both learned and
non-learned helplessness rats after ECS treatment [86] which
therefore seems to reflect a non-specific effect. In a further study
the involvement of the prefrontal cortex in major depressive disor-
der was investigated in rats exposed to the forced swimming test
[100]. Relative to controls, rats with a depressed mental status
exhibited increased Cho/tCr and Cho/NAA ratios. Unfortunately,
most proton MRS studies of rat models of depression are hampered
by the use of metabolite ratios. The results remain vague and de-
mand quantitative MRS studies of metabolite concentrations sim-
ilar to those performed in tree shrews to clarify which cerebral
metabolites are truly altered and subject to treatment.
4.10. Ethanol intoxication
A relatively large number of rat studies addressed the conse-
quences of acute and chronic ethanol exposure onto the brain
metabolism. Because human studies are usually hampered by
many poorly controllable variables and confounds including differ-ences in alcohol consumption, nutritional status, and anamnesis,
animal studies of ethanol intoxication are more suited for system-
atic investigations of the pathophysiology underlying alcohol-re-
lated brain damage.
Proton MRS studies of acute ethanol administration led to the
conclusion that ethanol diffuses freely with water, so that its con-
centration should be proportional to the water content of a given
brain area. Nevertheless, early MRS reports of brain ethanol con-
centrations largely differed, so that impaired MRS visibility of brain
ethanol due to motional restrictions was put forward as an expla-
nation [48]. However, a more recent quantitative study of ethanol
kinetics in rat brain indicated concentrations based on cerebral
MRS and blood alcohol levels to be in good agreement with the
administered dose [99], suggesting experimental differences in
previous work.
Chronic ethanol exposure is expected to alter cerebral metabo-
lism. Thus, 8 weeks of ethanol consumption resulted in a signifi-
cant decrease of the Ins/tCr ratio in rat brain, consistent with
perturbances in astrocytes [68]. However, NAA/tCr and Cho/tCr ra-
tios remained normal at this stage. A longitudinal study of rats
chronically exposed to ethanol revealed a decrease in the NAA/
Cho ratio at about 16 weeks, followed by an increase above normal
values after 44 weeks [84]. While alterations of the NAA/tCr ratio
were not observed, the persistently elevated NAA/Cho ratio for
up to 60 weeks after the start of alcohol intoxication was suggested
to mainly reflect reduced Cho, that is lower levels of glycerophos-
phocholine and phosphocholine.
In the context of alcohol intoxication and abuse, proton MRS
studies also determined neurochemical alterations in the thia-
mine-deficient rat brain [34,45,75]. In humans, thiamine (vitamin
B1) deficiency is a frequent nutritional complication in alcoholics
which can cause brain damage associated with Wernicke–Korsak-
off syndrome. In rats a combination of a thiamine-deficient diet
with daily intraperitonal injections of the thiamine antagonist
pyrithiamine was employed to induce neurological symptoms sim-
ilar to Wernicke’s encephalopathy [45]. In line with observations
after chronic ethanol intoxication, longitudinal studies of up to
26 days after the initiation of thiamine deficiency confirmed a
reduction of the brain Cho level as deducible from an increased
NAA/Cho ratio but unchanged NAA/tCr ratio. Interestingly, a
dose-dependent recovery of the NAA/Cho ratio was observed with-
in 2 h after thiamine administration [45], while injections of a cho-
line solution exerted only minor effects on the Cho resonance [75].
A satisfactory explanation for this observation is lacking and needs
further investigation.
In order to investigate why administration of glucose precipi-
tated Wernicke’s encephalopathy in some patients with subclinical
thiamine deficiency, the brain metabolites of thiamine-deficient
rats were assessed under glucose load [34]. Proton MRS yielded
dramatic increases of Lac, while animals presented with advanced
neurological signs. These results were found to be consistent with
a metabolic block at the reaction catalyzed by the thiamine-depen-
dent enzyme a-ketoglutarate dehydrogenase soon after the onset
of neurologic symptoms, and a further block at the pyruvate dehy-
drogenase arising late in the course of thiamine deficiency [34]. Be-
cause this latter block precludes the further metabolism of
pyruvate in the tricarboxylic cycle, it effectively eliminates the
use of oxidative glucose consumption, so that glycolysis accumu-
lates Lac.
4.11. Diabetes and other disease models
Diabetes mellitus is a complex metabolic disorder characterized
by elevated blood glucose (hyperglycemia). It can lead to long-
term complications in both the peripheral and the central nervous
system. Type 1 diabetes is caused by insulin deficiency due to a
Fig. 25. Rat model of type 2 diabetes mellitus. Localized proton MRS (7.0 T, STEAM, TR/TE = 6000/10 ms, 8.7 ll, 256 accumulations) of the hippocampus (mean results)
reveals increased Glc, Ins, and tCr concentrations in adult Zucker Diabetic Fatty (ZDF) rats (n = 5) relative to controls (n = 5). Note the elevated Glc resonance at 5.23 ppm
(arrows). Adapted from Ref. [92] with permission.
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type 2 diabetes refers to insulin resistance of the body cells.
Proton MRS of streptozotocin-induced diabetic rats 2 weeks as
well as 4 and 8 months after diabetes induction showed decreased
NAA/tCr ratios at all time points investigated [74]. The results were
interpreted as a relative reduction of NAA possibly indicating early
metabolic or functional abnormalities in neurons. A more recent
quantitative proton MRS study focused on possible changes in the
hippocampus of adult Zucker Diabetic Fatty (ZDF) rats [92]. The
ZDF rat is a widely used animal model for type 2 diabetes mellitus.
At about 10 weeks of age, ZDF rats become mildly hyperglycemic
and thereafter develop overt diabetes. Quantitative analyses of the
spectra shown in Fig. 25 revealed statistically significant increases
for the hippocampal concentrations of Glc, Ins, and tCr, while other
metabolites including NAA and Cho remained normal between 20
and 28 weeks of age [92]. These findings are in line with observa-
tions in human patients and suggest the ZDF rat to present a reliable
animal model for studying the effects of diabetes on brain metabo-
lism.Noteworthy, the determinationof absolutemetabolite concen-
trations was instrumental in this study as the use of metabolite
ratios (with tCr) would have masked the increase of Glc and Ins.
Excitotoxicity has been suggested to play a key role in the patho-
genesis of several cerebral disorders such as ischemia, Huntington’sdisease, trauma, and epilepsy. Two studies addressed the suscepti-
bility of immature rat brain to the neurotoxicity of NMDA [49] and
ouabain [87]. Amodest accumulationof Lacwas observed in thefirst
6 hafterNMDAadministration, followedbyanoverall decreaseof all
cerebral metabolites after 24 h. Treatment with the NMDA antago-
nistMK-801givenup to 90 min afterNMDA injection reversed these
metabolite changes in the entire ipsilateral hemisphere [49]. How-
ever,with reference toNMDA, it has been argued that the use of oua-
bain, a Na+/K+-ATPase inhibitor, elicits more glutamate receptor
overstimulation, so that ouabain-induced excitotoxicity might be
better suited to monitor neuroprotective strategies [87].
Other proton MRS studies of rat brain investigated metabolite
concentrations under hyponatremic conditions [50], in a hyperse-
rotonemic model of autism [78], after repetitive low-frequency
transcranial magnetic stimulation [88], in the developing hippo-
campus after perinatal iron deficiency [89], in pinelectomized rat
brains to assess a putative protective role of melatonin [95], and
after exposure to methylphenidate (Ritalin) [101].
5. Nonhuman primates
As pointed out earlier proton MRS studies of nonhuman prima-
tes offer anatomical, immunological, and functional similarities to
Table 2
Proton MRS linewidths of rhesus monkey brain in vivo for different magnetic field
strengths (in T) and volumes-of-interest (VOI).
Field/T VOI/mm3 Linewidth/Hz Reference
1.5 25 25 12 4–6 [107]
2.35 5 3 5 4–5 Marmoseta
2.35 7 5 7 6 Tree shrewa
3.0 18 18 18 5 [129]
4.7 15 15 15 16 [109]
7.0 5 5 5 8–11 [121,122]
a This lab, unpublished results.
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logical mechanisms of or novel therapeutic strategies against spe-
cific human brain disorders. So far, most studies used Old World
monkeys such as rhesus monkeys or baboons and covered a broad
range of disease models. Surprisingly, much less effort has been
made to investigate NewWorld monkeys such as commonmarmo-
set monkeys (Callithrix jacchus) which, because of their smaller
body size than macaques, have considerable practical advantages
as, for example, the applicability of dedicated small-bore animal
magnets. While the taxonomic status of the diurnal-active tree
shrews (Tupaia belangeri) is controversial, they are regarded as an
intermediate between insectivores and primates and placed in
the separate order Scandentia. Here tree shrews are included in
this section, because their brain anatomy and metabolism has
more in common with nonhuman primates than with rodents
and because tree shrews have become a valuable model for studies
of psychosocial stress [269,270].
5.1. Normal physiology
The first application of localized proton MRS to monkey brain
relied on a long echo time and therefore revealed only resonances
from NAA, tCr, and Cho [105]. Fig. 26 shows data from a state-of-
the-art proton MRS study of the brain of rhesus monkey (Macaca
mulatta) [121]. With the use of a STEAM sequence and LCModel
data analysis up to 16 metabolites could be identified in anesthe-
tized animals. As for rodents, the metabolite assignments and con-
centrations are in general agreement with in vitro proton NMR
studies of intact tissues and extracts from macaque brains [271–
273]. With respect to spectroscopic resolution at 7.0 T, the reduc-
tion of macroscopic susceptibility variations by decreasing the
VOI from 3.14 ml to 50 ll yielded linewidths of 14.2 and 7.6 Hz,
respectively [122]. As summarized in Table 2 linewidths of about
5 Hz were reported for rhesus monkey brain at 1.5 T [107] and
3.0 T [129] in agreement with linewidths of 6:3 0:9 Hz (n = 15,
unpublished results) obtained at 2.35 T in the brain of tree shrews.
MRSI at a nominal spatial resolution of about 4 ll allowed for a
segregation of gray and white matter in the visual cortex of rhesus
monkeys by sorting individual spectra according to their differentFig. 26. Localized proton MRS of rhesus monkey brain (7.0 T, STEAM, TR/TE = 4000/10 m
tCr, Cho, and Ins. The use of LCModel allows for the reliable detection of about 16 metametabolite levels [126]. Regional differences in the neurochemical
profiles of common marmoset monkeys are demonstrated in
Fig. 27. At the low field of 2.35 T excellent linewidths of about
3.7, 4.1, and 4.6 Hz were achieved for predominantly white matter,
gray matter, and thalamus, respectively. In line with quantitative
results obtained in macaque monkeys [122] and humans [245],
higher tNAA concentrations were found in the gray matter of mar-
moset monkeys than in white matter. In comparison to other
investigated brain regions elevated Cho concentrations were ob-
served in the thalamus.
An interesting observation is reported in Fig. 28 which dem-
onstrates increased Lac in the brain of macaque monkeys (Maca-
ca fascicularis) under isoflurane anesthesia in a dose-dependent
manner [129]. The midsagittal volume in frontoparietal cortex
comprised contributions from gray matter, white matter, and
CSF. With the use of diffusion-weighted localized proton MRS,
the authors also found larger ADCs (corresponding to enhanced
mobility) for all intracellular metabolites when increasing the
isoflurane dose from 1% to 2% (opposite to the ADC decreases ob-
served during ischemia). The results are explained by an in-
creased membrane permeability at high levels of isoflurane
which facilitates the exchange of metabolites between subcellu-
lar structures. Because a strict mitochondrial and cytosolic com-
partmentation is essential for efficient mitochondrial function,
this could also explain why isoflurane has been suggested to in-
hibit oxidative metabolism [274].s, 5 5 5 mm3, 256 accumulations) exhibits major resonances of MM, tNAA, Glu,
bolites. Adapted from Ref. [121] with permission.
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Fig. 27. Localized proton MRS of marmoset monkey brain (2.35 T, STEAM, TR/
TE = 6000/20 ms, 128 accumulations) reveals different neurochemical profiles for
predominantly white matter (WM, 4:5 3:0 4:5 mm3), gray matter (GM,
5:0 3:0 5:0 mm3), and thalamus (6:0 5:0 6:0 mm3). For example, while
tNAA concentrations are highest in gray matter, Cho concentrations are highest in
thalamus.
ig. 28. Rhesus monkey brain under different doses of isoflurane anesthesia.
calized proton MRS (3.0 T, STEAM, TR/TE = 2100/21 ms, 18 18 18 mm3, 32
ccumulations) under 1% and 2% isoflurane demonstrates increased Lac concentra-
ons at the higher dose (see difference spectrum). Adapted from Ref. [129] with
ermission.
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by a large number of unknown variables and the need for unreal-
istically large groups of subjects. To overcome these drawbacks,
putative influences of gender on aging, and separately on chronic
cortisol treatment, were investigated in the tree shrew brain
[102]. Physiological processes underlying brain aging are charac-
terized by an increasing imbalance among the various neurotrans-
mitters and neuromodulators resulting in significant structural and
biochemical changes. In particular, dysregulation of the hypothal-
amus–pituitary–adrenal (HPA) axis appears to be a common phe-
nomenon in aged mammals including humans. Therefore, excess
availability of the adrenocortical glucocorticoid hormones cortisol




pgender should be considered as another factor because, for exam-
ple, the much higher secretion of plasma concentrations of cortico-
steroid hormones in females suggests sexual dimorphism in the
regulation of the HPA axis activity. As demonstrated in Fig. 29, pro-
ton MRS of aged tree shrews indeed revealed lower concentrations
of tNAA and tCr in line with the occurrence of neuronal loss. In con-
trast, however, aged females exhibited increased concentrations of
Cho which, together with a tendency for increased tCr and Ins,
indicates glial proliferation [102]. After administration of cortisol,
male but not female tree shrews showed a specific reduction of
Cho. The observed gender differences with age are likely to result
from differences in the regulation of stress-related hormones
which is further supported by the gender-specific responses to
cortisol.
In nonhuman primates age-related changes of brain metabo-
lites have been reported for juvenile macaques within the first
1000 days of life [117], and also for aged rhesus monkeys [113].
Similar to observations in humans, increasing NAA/tCr ratios dur-
ing adolescence were interpreted as ongoing neuronal develop-
ment [117], while aged rhesus monkeys presented with
unchanged NAA/tCr and Cho/tCr ratios but a remarkable increase
of the Ins/tCr ratio [113]. Because the latter study did not distin-
guish between males and females and also relied on metabolite ra-
tios, the findings must be considered preliminary. For example, a
simultaneous decrease of tNAA and tCr, as typical for neuronal loss
and observed in aged male tree shrews [102], would have been
masked by the use of metabolite ratios.
5.2. Cerebral ischemia
So far, proton MRS studies of the ischemic monkey brain have
confirmed the well-known increases of Lac and decreases of NAA
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Fig. 29. Localized proton MRS of tree shrew brain (2.35 T, STEAM, TR/TE = 6000/20 ms, 7:0 5:0 7:0 mm3, 64 accumulations) reveals gender-specific neurochemical profiles
for aged animals (male n = 5, female n = 5) as well as for cortisol-treated animals (male n = 5, female n = 6). Arrows indicate statistically significant differences in comparison
with adult animals (male n = 5, female n = 6). Adapted from Ref. [102] with permission.
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event. No scientific advances were made beyond the findings in ro-
dents. However, future proton MRS of focal cerebral ischemia in
monkeys may become important for the optimization of novel
treatment options including drug efficiency and duration of the
therapeutic window. This also involves the long-time monitoring
of metabolite alterations in tissue at risk, that is in the penumbra
adjacent to the core ischemic region.
5.3. Multiple sclerosis
In combination with T2-weighted MRI and histology, localized
proton MRS has been performed in macaques (M. fascicularis)
with EAE [109]. Acutely fatal EAE lesions were large and showed
increased Cho concentrations at disease onset. Chronic EAE le-
sions were preceded by multiple inflammatory attacks and
exhibited consistently low levels of NAA after the initial attack.
The combination and temporal correlation of MRI lesion activity
and MRS-determined metabolite concentrations was found to be
useful for predicting the histologic lesion type and subsequent
disease course. In general, the use of nonhuman primates for re-
search on multiple sclerosis benefits from an immunological sys-
tem comparable to that of humans. On the other hand, these
similarities may cause a corresponding degree of heterogeneityas observed in human patients with multiple sclerosis which
complicates study design and lowers statistical power in thera-
peutic trials.
5.4. Parkinson’s disease
Long-term neurodegenerative changes have been studied in a
primate model (M. fascicularis) of Parkinson’s disease using multi-
ple administrations of the mitochondrial complex-1 inhibitor
MPTP [114]. For up to 10 months after MPTP proton MRS revealed
dramatic increases of Lac and macromolecules in the striatum. By 2
years after MPTP, Lac and macromolecule levels had returned to
normal values, while striatal tissue exhibited increased Cho/tCr
and decreased NAA/tCr ratios [114]. In a MPTP model of marmoset
monkeys studied before and 3.5 weeks after intoxication, a daily
oral dose of the vigilance enhancer modafinil demonstrated neuro-
protective potential as indicated by a preserved NAA/tCr ratio
[130].
Exposure to high levels of manganese is known to produce a
complex neurological syndrome with psychiatric disturbances,
cognitive impairments, and Parkinsonian features. After chronic
manganese exposure proton MRS of macaques (M. fascicularis)
yielded a decreased NAA/tCr ratio in the parietal cortex [128].
Although the exact reason for the manganese-induced pathology
Fig. 31. Rhesus monkey model of SIV infection. Localized proton MRS (1.5 T, PRESS,
TR/TE = 3000/35 ms, 15 15 15 mm3, 128 accumulations) of the frontal lobe
before as well as 11 and 25 days after i.v. inoculation with SIVmac251 reveals
alterations of Cho/tCr and Ins/tCr ratios (as indicated by respective bars). Adapted
from Ref. [124] with permission.
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dysfunction.
5.5. Huntington’s disease
After chronic and systemic administration of the mitochondrial
toxin 3NP quantitative proton MRS of baboons demonstrated a
progressive and region-specific decrease of striatal NAA, tCr, and
Cho that occurred already 3 weeks before the first detection of
Lac. Because these metabolic disturbances were not observed in
an occipital control region as shown in Fig. 30, the NAA decrease
does not appear to simply reflect the degree of mitochondrial
impairment but indicates a preferential vulnerability of the stria-
tum to 3NP-induced toxicity [115] similar to observations in rats.
Further work demonstrated that early NAA depletion in this model
corresponds to a reversible state of neuronal dysfunction preceding
ultimate cell degeneration and death. Such findings suggest that
in vivo NAA concentrations may become a valuable tool for the
assessment of early neuronal dysfunction and a putative marker
for the success of neuroprotective therapies [116].
5.6. HIV encephalitis
HIV infections that lead to AIDS are associated with abnormal-
ities in the immune system that may cause neurological disorders
known as neuroAIDS. The clinical syndromes include sensory neu-
ropathy, myelopathy, HIV dementia, and cognitive/motor disorder.
Rather than infecting neurons themselves, neuronal injury is
thought to arise by indirect mechanisms. The virus infects perivas-
cular macrophages and microglia within the CNS, and it is believed
that substances including cytokines and viral products generated
by these cells ultimately result in neuronal injury. Nonhuman pri-
mates infected with the simian immunodeficiency virus (SIV) are
essential models in the development of novel treatment strategies
such as highly active antiretroviral therapy.
A prospective longitudinal proton MRS study of the SIV maca-
que model examined SIVmac251-infected animals to terminal
AIDS or an endpoint of 2 years [123]. During acute infection cere-
bral metabolites were characterized by a dominant increase of the
Cho/tCr ratio in frontal cortex. Subsequently, brain metabolite pro-
files diverged between individual animals and metabolite ratios
were not significantly different from baseline at any time point
after 2 weeks post inoculation. The increases of Cho/tCr and Ins/
tCr ratios 11 days post inoculation were confirmed in another
study using a larger number of animals [124]. Although these find-Fig. 30. Baboon model of Huntington’s disease. Localized proton MRS (1.5 T, PRESS, T
chronic 3NP administration reveals decreased NAA, tCr, and Cho (arrows), while metaboli
Lac (insert). Adapted from Ref. [115] with permission.ings suggest brain injury and repair during acute SIV infection, Ins/
tCr ratios remained elevated at day 25, while Cho/tCr ratios de-
creased below normal values, as shown in Fig. 31 [123]. In a further
study SIV infection and CD8 lymphocyte depletion resulted in ra-
pid neuronal injury as indicated by a pronounced decrease of the
NAA/tCr ratio during the first 10 weeks [125]. This finding is in line
with MRS studies of respective mouse models. Animals which
underwent an antiretroviral combination therapy immediatelyR/TE = 2500/135 ms, 32 13 10 mm3, 256 accumulations) of the striatum after
tes in the occipital cortex remain normal. The use of TE = 270 ms identifies increased
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ig. 32. Tree shrew model of psychosocial stress and antidepressant treatment.
ocalized proton MRS (2.35 T, STEAM, TR/TE = 6000/20 ms, 7:0 5:0 7:0 mm3, 64
ccumulations) of the brain (mean results) reveals stress-induced decreases of
AA, tCr, and Cho (n = 11) which are prevented by antidepressant treatment with
aneptine (n = 6), clomipramine (n = 5), and the neurokinin-1 receptor antagonist
-760,735 (n = 5). Arrows indicate statistically significant differences in comparison
ith controls (n = 9). Adapted from Refs. [103,104] with permission.
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rapid recovery of the NAA/tCr ratio after 2 weeks of treatment
reaching almost pre-infection levels after 4 weeks [125]. Although
preliminary and based on metabolite ratios, these studies demon-
strate the ability of in vivo MRS to monitor therapeutic approaches
in an advanced animal model of neuroAIDS.
5.7. Psychosocial stress and depression
Chronic stress causes neurochemical, hormonal, and physio-
logic changes and acts as a potent trigger of major depressive dis-
order. In recent years, adult male tree shrews have been developed
as a valuable animal model for depression based on chronic psy-
chosocial stress [269,270], that is daily exposure to a dominant
male for several weeks. Using quantitative proton MRS of absolute
metabolite concentrations, the brains of stressed tree shrews
exhibited significantly decreased in vivo concentrations of tNAA,
tCr, and Cho [103,104]. Although the concomitant reductions are
clearly visible in the upper part of Fig. 32, they would have escaped
detection when using metabolite ratios (with tCr), a finding which
may explain the conflicting results of clinical MRS studies of de-
pressed subjects. The observed tNAA reduction reflects a lower
neural cell density and/or neuronal dysfunction. Accordingly, alter-
ations of the Cho level may result from disturbances in the forma-
tion and degradation of cell membranes or, because Cho is highly
concentrated in oligodendrocytes [240], a respective reduction of
cell density. Interestingly, a low number of oligodendrocytes was
reported postmortem in patients with major depressive disorder
[275]. A reduced cellular density of neurons and/or oligodendro-
cytes is in line with the lowered concentration of tCr as a constit-
uent of all cells. Moreover, the unchanged concentration of the
marker compound Ins indicates a preservation of astrocytes.
Medication in depression attempts to normalize the concentra-
tions of neurotransmitters, notably serotonin and norepinephrine,
but also dopamine. To mimic a realistic situation of antidepressant
medication in an animal model, tree shrews were subjected to a
period of psychosocial stress to elicit stress-induced endocrine
and central nervous alterations before the onset of daily oral
administration of the drugs. Psychosocial stress was continued
during treatment. As demonstrated in the lower parts of Fig. 32,
the stress-induced decreases of tNAA, tCr, and Cho were prevented
by antidepressant treatment with tianeptine [103], clomipramine
[104], and the neurokinin 1 (NK1) receptor antagonist L-760,735
[104]. The latter two drugs had an even more enhancing effect
on brain metabolites than tianeptine and also led to elevated Ins
concentrations [104]. Similar treatment results were obtained for
the novel NK1 receptor antagonist SLV-323 [276]. Taken together,
the proton MRS results confirm a direct neurobiologic effect of
chronic stress and suggest a similar protective effect for different
classes of antidepressants. Moreover, it may be speculated that
the used antidepressants preserved or even stimulated oligoden-
dritic activity, and consequently counteracted neural resilience.
5.8. Developmental disturbances
Similar to the results in rat brain, proton MRS of macaque brain
revealed normal NAA, tCr, and Cho levels after acute ethanol
administration [107]. In contrast, however, adult monkeys (Macaca
nemestrina) at 2 and 4 years of age but with a prenatal history of
ethanol exposure exhibited increased Cho/tCr ratios [108]. These
alterations occurred in the absence of gross structural brain abnor-
malities and were correlated with ethanol-related cognitive and
behavioral dysfunction. The study clearly demonstrated that fetal
brain development is influenced by ethanol and that long-lasting
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primates exposed to early-life stressors. For a few months, Bonnet
macaque (Macaca radiata) mother–infant dyads were exposed to
uncertain requirements for food procurement, that is variable for-
aging demand. Ten years later, these animals displayed signifi-
cantly decreased NAA/tCr and increased Glx/tCr ratios in the
anterior cingulate cortex [118]. In the medial temporal lobe, the
Cho/tCr ratio was increased. These findings indicate that adverse
early rearing in primates has an enduring impact on adult metab-
olite concentrations that are considered to reflect neuronal integ-
rity, membrane structure, and glial function [118]. Interestingly,
the observed metabolite alterations occurred in the same brain re-
gions implicated in trauma-related psychiatric disorders.
Another proton MRS study investigated the long-term effects of
early mesial temporolimbic lesions on neurons of the prefrontal
cortex [112]. A reduction of the NAA/tCr ratio in the prefrontal cor-
tex was exclusively observed in rhesus monkeys lesioned neona-
tally, that is within 3 weeks of birth, but not in animals lesioned
at adulthood. The authors concluded that, apart from developmen-
tal aspects, this finding may have implications for similarly re-
duced NAA levels in the hippocampus and prefrontal cortex of
patients with schizophrenia.
5.9. Radiation effects
The neurochemical consequences of radiation therapy on nor-
mal brain tissue were assessed in monkeys (Macaca fuscata) using
sequential proton MRS after interstitial brachytherapy [111]. The
hemisphere with the sealed radioactive source showed signifi-
cantly decreased NAA/tCr and Cho/tCr ratios one week after
implantation, while the contralateral side exhibited a trend toward
decreased metabolite ratios. Lac was not detected. The results sug-
gest the use of proton MRS for a differentiation of radiation necro-
sis from residual and/or recurrent glioblastomas with the use of
contralateral comparisons after radiation therapy [111].
6. Other animal models
6.1. Gerbils, squirrels, guinea pigs, and rabbits
The Mongolian gerbil (Meriones unguiculatus) has been used as
a popular model for cerebral ischemia [131,196–198]. The cere-Fig. 33. Ground squirrel brain during hibernation. Localized proton MRS (9.4 T, STEAM, T
(fall and spring), hibernation, and interbout arousal (IBA) reveals an increase of the PC
(Tb = body temperature). Adapted from Ref. [132] with permission.bral vasculature of the gerbil is characterized by an incomplete
circle of Willis, so that animals lack a collateral supply of arterial
blood to the forebrain and hindbrain circulations from both the
vertebral and carotid arteries. Although this might be of advan-
tage for experimental purposes, it has been stated that the neu-
roanatomy of the gerbil is unfavorable for proton MRS [199].
However, studies of global ischemia achieved sufficient spectral
resolution to detect increased Lac/NAA ratios [196,197] as well
as decreased Cho/tCr ratios and increased T2 values of Cho
[198]. In a quantitative proton MRS study during and after ische-
mia altered NAA concentrations could be correlated with graded
hippocampal damage and stereologically determined neuronal
density [131].
Hibernation is a state of inactivity and metabolic depression in
animals to conserve energy during winter. It is characterized by a
lower body temperature, slower breathing, and lower metabolic
rate. The effects of near-freezing temperatures (7 C) on brain en-
ergy metabolism and neurotransmission were studied in hibernat-
ing 13-lined ground squirrels (Spermophilus tridecemlineatus)
[132]. As demonstrated in Fig. 33, the PCr/Cr ratio determined at
9.4 T was increased during torpor indicating enhanced stores of
high-energy phosphates. The ratio remained increased, albeit to a
lesser degree, during interbout arousal (IBA), but returned to a nor-
mal level in the spring. The decreased Glu and Gln concentrations
during torpor suggest that the generally lowered metabolism in
hibernation is accompanied by a reduction of the excitatory neuro-
transmitter levels [132]. Localized proton MRS of hibernating
mammals may become helpful in the search for novel neuroprotec-
tive strategies after stroke.
In a model of multiple sclerosis Dunkin–Hartley guinea pigs
were followed sequentially 6 weeks post EAE inoculation by non-
localized proton MRS [200]. The detection of an increased Cho/
tCr ratio in vivo was associated with an increase of choline, betaine,
and phosphocholine as revealed by in vitro NMR spectroscopy of
PCA extracts of respective brain tissue.
New Zealand white rabbits were intensively studied to monitor
cerebral Lac elevation (and recovery) during hypoxemia [201], hy-
per- and hypocarbia [202], bicuculline-induced seizures [203], and
cortical electroshock [204,205]. A further study reported a good
agreement between cerebral and blood ethanol concentrations at
all times after intraarterial or intragastric ethanol administration
[206].R/TE = 5000/2 ms, 4:0 1:5 3:0 mm3, 160 accumulations) during the active phase
r/Cr ratio during hibernation (zoomed insert) indicating enhanced energy storage
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The majority of proton MRS applications to cat brain investi-
gated hypoxia and ischemia. The first studies used a surface coil
after scalp and muscle retraction to acquire otherwise nonlocalized
spectra during hypoxia and/or ischemia [207–209]. These as well
as subsequent fully localized recordings [133–135,137] reported
metabolite changes upon death (global ischemia) in close agree-
ment with the results obtained in rodent models of ischemia. In
particular, relative to the pre-ischemic signal, Lac increased rapidly
in the first 2 h of ischemia and was stabilized afterwards, while
NAA and tCr decreased by about 35% within the first 8 h [134]. Se-
rial measurements of water ADCs and Lac concentrations agreed
with the expected biphasic changes due to changes of the ion
and water homeostasis during global ischemia [135]. Moreover,
alterations in the low-field part of the proton MR spectrum shown
in Fig. 34 indicated enhanced signals from purine nucleotides as
the ATP breakdown products [133,135,137]. The combination of
proton MRS with perfusion- and diffusion-weighted MRI was
found to be advantageous for a time-resolved assessment of the
circulatory and metabolic recovery of cat brain after cardiac arrest
[139].
In a cat model of Parkinson’s disease using MPTP intoxication
the authors reported reduced striatal NAA/tCr and Glx/tCr ratios
as well as elevated Lac in all investigated animals [140]. Infection
with the feline immunodeficiency virus led to frontal lobe neuronal
injury in terms of reduced NAA/tCr and increased Cho/tCr ratios in
infected cats. Moreover, neuropathologic changes, including neu-
ronal damage and astrogliosis, were dependent on virus input titer
[138].
The first studies of dog brain addressed the feasibility of sol-
vent-suppressed proton MRS [210], T1 measurements of NAA, tCr,
and Cho [211], the role of Lac as a preferential metabolic fuel for
the neonatal dog brain [212], and the MRS visibility of ethanol in
brain tissue [214,215]. Quantitative proton MRS of normal brain
revealed general agreement between in vivo and in vitro results
[142]. As shown in Fig. 35 the postmortem catabolism of cerebral
metabolites was studied as a potential diagnostic aid in legal med-
icine [144]. Disease models comprised status epilepticus [213],
prolonged generalized seizures [146], and fulminant hepatic fail-
ure [145]. In a canine brain tumor model reduced NAA and tCr as
well as elevated Lac concentrations significantly correlated withFig. 34. Cat model of global cerebral ischemia (postmortem). Localized proton MRS
(4.7 T, STEAM, TR/TE = 1000/4.8 ms, 20 10 20 mm3, 16 accumulations) of the
brain reveals increased resonances (arrows) of Lac and the combined purine
nucleotides/nucleosides and hypoxanthine (PN) 1 h postmortem. Adapted from Ref.
[135] with permission.
Fig. 35. Dog model of global cerebral ischemia (postmortem). Localized proton MRS
(1.5 T, STEAM, TR/TE = 2000/20 ms, 15 15 15 mm3, 128 accumulations) of the
thalamus reveals increases of Lac and the Ins/tCr ratio 30 min to 48 h postmortem,
while NAA/tCr and Cho/tCr ratios remain constant within the first 24 h. Adapted
from Ref. [144] with permission.total lesion volume [141,143]. These tumor spectra were similar
to those observed in human glioblastomas, with the exception that
Cho was not elevated [143].
6.3. Sheep and swine
As in early studies of global ischemia in cat brain, simple surface
coil proton MRS approaches were used to assess episodes of ische-
mia and hypoxia–ischemia in lambs (Clun forest breed). These
studies elucidated the relationships between cerebral oxidative
metabolism and anaerobic glycolysis [216] and examined the ef-
fects of systemic glucose and sodium bicarbonate administration
on ischemic brain metabolism [217]. More recent localized proton
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texel breed). First of all, the relative intensity of NAA turned out
to be much higher in fetal lamb brain than in humans indicating
a more mature status at an earlier stage of gestation [147]. During
hypoxia elevated levels of Lac were observed. As shown in Fig. 36 a
reduction of oxygen supply to the anesthetized pregnant ewe
caused a sudden and dramatic increase of Lac during hypoxia fol-
lowed by a slower decrease of NAA [148]. Together with simulta-
neous physiological measurements the results support the view
that a hypoxia-induced switch to anaerobic metabolism in the fetal
lamb brain only occurs if the arterial blood pH or the base excess
falls below a certain value.
Several surface coil MRS studies investigated the effects of hy-
poxia–ischemia in the brain of newborn Large White pigletsFig. 36. Lamb model of fetal hypoxia. Localized proton MRS (1.5 T, STEAM, TR/
TE = 2500/30 ms, 3.6–7.5 cm3, 64 accumulations) of the brain before (t = 0) and
during fetal hypoxia reveal dramatic increases of Lac within 60 min after reduced
oxygen supply to the pregnant ewe. While NAA decreases during hypoxia, Ins, Cho,
and tCr remain constant. Relatively high levels of NAA in the fetal brain indicate an
earlier brain maturation than in humans. Adapted from Ref. [148] with permission.[218–220]. By combining proton and phosphorus MRS dramatic
changes of the cerebral energy metabolism were detected [218].
After a normalization within hours after hypoxia–ischemia a de-
layed secondary energy failure occurred [219]. Moreover, mild
hypothermia after hypoxia–ischemia reduced the delayed rise in
cerebral Lac and showed neuroprotective potential [220]. A more
recent study of a similar model using Yorkshire Large White piglets
confirmed the metabolite alterations and their time courses during
and after hypoxia–ischemia [150]. Although the authors suggested
elevated nitric oxide to contribute to free radical-induced brain
damage, an attempt to inhibit nitric oxide synthase by Nx-nitro-
L-arginine appeared to compromise the cerebral energy status dur-
ing and after cerebral hypoxia–ischemia.
Finally, miniature swine (Hanford strain) were used to investi-
gate diffuse brain trauma [149]. The temporal course of metabolite
changes revealed widespread axonal injury in the absence of mark-
edly elevated Lac. As shown in Fig. 37 the NAA/tCr ratio decreased
in the acute phase and remained without recovery during the
investigated period.
6.4. Summary
Gerbils, squirrels, guinea pigs, and rabbits are animal models for
human brain disorders that are rarely studied by proton MRS
in vivo. In view of the rapid progress in high-field MRS of geneti-
cally modified mice and the large data base available from rats, it
is unlikely that these species will gain more importance. Similar
arguments hold true for cats and dogs as well as for sheep and
swine which further face the problem that their size precludes
the use of a dedicated animal MRI system. In general, the animalsig. 37. Swine model of diffuse brain trauma. Localized proton MRS (4.0 T, STEAM,
R/TE = 2000/31 ms, 15 15 15 mm3, 128 accumulations) of the brain before and
fter trauma demonstrates an acute decrease of the NAA/tCr ratio which persists for
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specific questions including research outside the field of neurosci-
ence or neurology.
7. Concluding remarks
Localized proton MRS of animal brain in vivo has become a
valuable tool for both preclinical research and basic neuroscience.
Nevertheless, the reliable assessment of cerebral metabolism in
animal models of human brain disorders requires robust solutions
to a number of technical issues. In this respect the past two dec-
ades have witnessed tremendous advances ranging from the devel-
opment of adequate spectral localization methods to the
identification and assignment of metabolite resonances and the
development of suitable quantification methods for translating
resonance intensities into absolute metabolite concentrations.
Nowadays, localized proton MRS is increasingly used for the eval-
uation of neurochemical profiles in animal models using (trans-
genic) mice, rats, and nonhuman primates. It is foreseeable that
the hitherto dominating studies of rat brain will be replaced by
the increasing availability of genetically modified mice and, if nec-
essary, complemented by studies of nonhuman primates because
of their similarity to humans. Thus, noninvasive MRI and MRS
studies will help to bridge the gap from molecular biology and
neurogenetics to preclinical neurological research. In general, pro-
ton MRS seldom provides unambiguous diagnostic clues, but more
often unravels metabolite profiles characteristic of alterations in
intracellular metabolism or cellular composition. MRS findings
are expected to advance our understanding of the pathophysiolog-
ical mechanisms underlying human neurological and psychiatric
disorders and enhance our ability to guide the effectiveness of no-
vel therapeutic interventions.
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ADC: apparent diffusion coefficient
AIDS: acquired immune deficiency syndrome
Ala: alanine
ALS: amyotrophic lateral sclerosis
APP: amyloid precursor proteinAsp: aspartate
ATP: adenosine triphosphate






EAE: experimental allergic encephalomyelitis
ECS: electroconvulsive shock





Glx: glutamate and glutamine
GPC: glycerophosphocholine
HIV: human immunodeficiency virus
HPA: hypothalamus–pituitary–adrenal







MECP2: methyl-CpG-binding protein 2
MM: macromolecules
MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MRI: magnetic resonance imaging
MRS: magnetic resonance spectroscopy













SIV: simian immunodeficiency virus
SNR: signal-to-noise ratio
STEAM: stimulated echo acquisition mode
Suc: succinate
Tau: taurine
tCr: creatine and phosphocreatine
TE: echo time
tNAA: N-acetylaspartate and N-acetylaspartylglutamate
TR: repetition time
VOI: volume-of-interest
WT: wild-type
